

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 September 2001 (13.09.2001)

PCT

(10) International Publication Number
WO 01/66543 A2

- (51) International Patent Classification⁷: C07D 451/02, A61P 37/06
- (21) International Application Number: PCT/US01/05735
- (22) International Filing Date: 22 February 2001 (22.02.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/186,778 3 March 2000 (03.03.2000) US
- (71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ 08869-0602 (US).
- (72) Inventors: CARSON, John, R.; 551 Rittenhouse Boulevard, Norristown, PA 19403 (US). COATS, Steven, J.; 1029 Brayton Court, Quakertown, PA 18951 (US). NEILSON, Lou, Anne; 1210 Diamond Street, Sellersville, PA 18960 (US). WU, Wu-Nan; 2043 Spring Valley Road, Lansdale, PA 19446 (US). BOYD, Robert, E.; 84 Wynmere Drive, Horsham, PA 19044 (US). PITIS, Philip, M.; 108 Sunrise Drive, North Wales, PA 19454 (US).
- (74) Agents: JOHNSON, Philip, S. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/66543 A2

(54) Title: 3-(DIARYLMETHYLENE)-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES

(57) Abstract: This invention is directed to 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives useful as δ -opioid or μ -opioid receptor modulators. Depending on their agonist or antagonist effect, the compounds are useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.

3-(DIARYLMETHYLENE)-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES

FIELD OF THE INVENTION


The present invention is directed to compounds useful as delta-opioid and mu-opioid receptor modulators. More particularly, the present invention is directed to 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives useful as

5 delta-opioid or mu-opioid receptor modulators.


BACKGROUND OF THE INVENTION

WO 97/23466 describes compounds as having an analgesic effect of a general and one preferred formula:

10




WO 98/28270 describes compounds as having an analgesic effect of a general and one preferred formula:




WO 98/28275 describes compounds as having an analgesic effect of a general and one preferred formula:

5




Amide derivatives of 3-aminotropane have been prepared and described as having potential pharmacological activity (Gutkowska, B., et al., *Acta Pol.*

10 *Pharm.*, 1984, 41(6), 613-617), of the formula:




WO 93/15062 describes compounds as delta-opioid (δ -opioid) and mu-opioid (μ -opioid) receptor agonists of (approximately) the general formula:

5



The synthesis and binding affinities for 4-Diarylaminotropane compounds as δ -opioid agonists have been described (Boyd, R.E., Carson, J.R., Codd, E.E., Gauthier, A.D., Neilson, L.A and Zhang, S-P., *Biorg. Med. Chem. Lett.*, **2000**, 10: 1109-1111) of the general formula:



3

wherein R is hydrogen, methyl, propyl, hexyl, 2-ethylbutyl, allyl, 3,3-dimethyl, cyclohexylmethyl, phenethyl, phenylpropyl, 2,2-diphenylethyl, 3,4-dimethoxyphenethyl, 4-fluorophenethyl, 2-furylmethyl, 3,4-methylenedioxybenzyl, cyano and X is *N,N*-dimethylamino, *N,N*-diethylamino, *N,N*-dipropylamino, *N*-methyl-*N*-ethylamino, *N*-methyl-*N*-propylamino, *N*-methyl-*N*-phenylamino, *N*-ethyl-*N*-(4-methyl)benzylamino, *N*-butyl-*N*-ethylamino, *N*-butyl-*N*-propylamino, [N-ethyl-*N*-(2-methyl)allyl]amino, hydroxy, *O*-*t*-butyl and 1-pyrrolidinyl; and, Y is hydrogen, methoxy and methylthio.

Other selective 4-[(8-alkyl-8-azabicyclo[3.2.1] octyl-3-yl)-3-arylanilino]-*N,N*-diethylbenzamide δ -opioid ligands have also been described (Thomas, J.B., Atkinson, R.N., Rothman, R.B., Burgess, J.P., Mascarella, S.W., Dersch, C.M., Xu, H. and Carroll, F.I., *Biorg. Med. Chem. Lett.*, **2000**, 10: 1281-1284).

The present invention is directed to compounds useful as delta-opioid and mu-opioid receptor modulators. More particularly, the present invention is directed to delta-opioid and mu-opioid receptor modulators.


It is an object of the present invention to provide 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives useful as δ -opioid or μ -opioid receptor modulators. It is also an object of the present invention to provide δ -opioid and μ -opioid receptor selective agonists as analgesics having reduced side-effects. It is another object of the present invention to provide δ -opioid and μ -opioid receptor selective antagonists as immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases, having reduced side-effects. It is also another object of the present invention to provide a useful pharmaceutical composition comprising a compound of the present invention useful as a δ -opioid or μ -opioid receptor modulator. It is a further object of the present invention to provide a useful

pharmaceutical composition comprising a δ -opioid or μ -opioid receptor modulator compound of Formula (I) in combination with a μ -opioid receptor modulator or a δ -opioid or μ -opioid receptor modulator compound of Formula (I) wherein the combination has a synergistic therapeutic effect.

5

SUMMARY OF THE INVENTION

The present invention provides an opioid receptor modulator compound selected from the group consisting of a δ -opioid and a μ -opioid receptor modulator compound of Formula (I):



10

(I)

wherein:

R¹ is selected from the group consisting of hydrogen, C₁₋₈alkyl, halo₁₋₃(C₁₋₈)alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy(C₂₋₈)alkenyl, C₂₋₈alkynyl, C₁₋₈alkoxy(C₂₋₈)alkynyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, cycloalkylcarbonyl(C₁₋₈)alkyl, cycloalkyl(C₂₋₈)alkenyl, cycloalkyl(C₂₋₈)alkynyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl, heterocyclylcarbonyl(C₁₋₈)alkyl, heterocyclyl(C₂₋₈)alkenyl, heterocyclyl(C₂₋₈)alkynyl, aryl, aryl(C₁₋₈)alkyl, arylcarbonyl(C₁₋₈)alkyl, aryl(C₂₋₈)alkenyl, aryl(C₂₋₈)alkynyl, arylaminocarbonyl(C₁₋₈)alkyl, heteroaryl(C₁₋₈)alkyl, heteroarylcarbonyl(C₁₋₈)alkyl, heteroaryl(C₂₋₈)alkenyl, heteroaryl(C₂₋₈)alkynyl, heteroarylaminocarbonyl(C₁₋₈)alkyl, (R^{1a})₂-N-(C₁₋₈)alkyl, R^{1a}-O-(C₁₋₈)alkyl, R^{1a}-S-(C₁₋₈)alkyl, R^{1a}-SO-(C₁₋₈)alkyl and R^{1a}-SO₂-(C₁₋₈)alkyl; wherein

heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, oxo, cyano, trifluoromethyl and trifluoromethoxy; and, wherein aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy;

R^{1a} is independently selected from the group consisting of hydrogen, C₁₋₈alkyl, C₁₋₈alkoxy(C₁₋₈)alkyl, hydroxy(C₁₋₈)alkyl, halo₁₋₃(C₁₋₈)alkyl, halo₁₋₃(C₁₋₈)alkoxy(C₁₋₈)alkyl, C₂₋₈alkenyl, C₂₋₈alkynyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl, heterocyclyl(C₁₋₈)alkenyl, heterocyclyl(C₁₋₈)alkynyl, aryl, aryl(C₁₋₈)alkyl, aryl(C₁₋₈)alkenyl, aryl(C₁₋₈)alkynyl, arylcarbonyl(C₁₋₈)alkyl, heteroaryl, heteroaryl(C₁₋₈)alkyl, heteroaryl(C₁₋₈)alkenyl, heteroaryl(C₁₋₈)alkynyl and heteroarylcarbonyl(C₁₋₈)alkyl; wherein heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, oxo, cyano, trifluoromethyl and trifluoromethoxy; and, wherein aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy;

R² is selected from the group consisting of aryl and heteroaryl optionally substituted with one to three substituents independently selected from the

group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminocarbonyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy; alternatively, when aryl and heteroaryl are substituted with two substituents attached to adjacent carbon atoms, the two substituents can together form a single fused moiety; wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

10 R³ is selected from the group consisting of aryl and heteroaryl optionally substituted with one or two substituents in addition to the -A-Z moiety independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminocarbonyl, 15 C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy; alternatively, when aryl and heteroaryl are substituted with two optional substituents attached to adjacent carbon atoms, the two substituents can together form a single fused moiety; wherein the moiety is selected from the group consisting of 20 -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

A is selected from the group consisting of -C(=X)- and -SO₂-;

X is selected from the group consisting of O and S;

Z is selected from the group consisting of -O(R⁴) and -N(R⁵)(R⁶);

R⁴ is selected from the group consisting of hydrogen, C₁₋₈alkyl (optionally substituted with one to three halogen substituents), C₁₋₈alkoxy(C₁₋₈)alkyl, 30 C₂₋₈alkenyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl, aryl, aryl(C₁₋₈)alkyl, heteroaryl, heteroaryl(C₁₋₈)alkyl, amino(C₁₋₈)alkyl, C₁₋₈alkylamino(C₁₋₈)alkyl, di(C₁₋₈)alkylamino(C₁₋₈)alkyl and hydroxy(C₁₋₈)alkyl; wherein heterocyclyl is optionally substituted with one to

three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen, hydroxy, oxo and cyano; and, wherein aryl is optionally substituted with one to four substituents independently selected from the group consisting of

5 C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, -OCH₂O-, -O(CH₂)₂O-, trifluoromethyl, halogen, hydroxy and cyano; and,

R⁵ and R⁶ are independently selected from the group consisting of hydrogen, C₁₋₈alkyl (optionally substituted with one to three halogen substituents),

10 C₁₋₈alkoxy(C₁₋₈)alkyl, C₂₋₈alkenyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl, aryl, aryl(C₁₋₈)alkyl, heteroaryl, heteroaryl(C₁₋₈)alkyl, amino(C₁₋₈)alkyl, C₁₋₈alkylamino(C₁₋₈)alkyl, di(C₁₋₈)alkylamino(C₁₋₈)alkyl, aminoimino, aminocarbonyl, aminocarbonyl(C₁₋₈)alkyl, aryloxycarbonylamino(C₁₋₈)alkyl,

15 heteroaryloxycarbonylamino(C₁₋₈)alkyl, hydroxy(C₁₋₈)alkyl and trifluoro(C₁₋₄)alkoxy; wherein heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₈alkoxy, C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen, hydroxy, oxo and cyano; and, wherein aryl is optionally substituted with one to four substituents independently selected from the group consisting of

20 C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, -OCH₂O-, -O(CH₂)₂O-, trifluoromethyl, halogen, hydroxy and cyano; alternatively, R⁵ and R⁶ may, together with the nitrogen to which they are attached, form a fused heterocyclyl moiety optionally substituted with one to four substituents

25 independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen, hydroxy and cyano;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

30

DETAILED DESCRIPTION OF THE INVENTION

Embodiments of a compound of Formula (I) include those compounds

wherein, preferably, R¹ is selected from the group consisting of hydrogen, C₁₋₈alkyl, C₂₋₈alkenyl, C₂₋₈alkynyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl, heterocyclylcarbonyl(C₁₋₈)alkyl, aryl(C₁₋₈)alkyl, arylcarbonyl(C₁₋₈)alkyl, aryl(C₂₋₈)alkynyl, arylaminocarbonyl(C₁₋₈)alkyl, heteroaryl(C₁₋₈)alkyl, (R^{1a})₂-N-(C₁₋₈)alkyl and R^{1a}-O-(C₁₋₈)alkyl; wherein heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy, oxo and cyano; and, wherein aryl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy and cyano.

More preferably, R¹ is selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *t*-butyl, *n*-hexyl, butenyl, allyl, 3,3-dimethyl, cyclopropyl, cyclopropyl(C₁₋₃)alkyl, cyclohexyl, cyclohexyl(C₁₋₃)alkyl, pyrrolidinyl, pyrrolidinyl(C₁₋₃)alkyl, 1,3-dioxolanyl(C₁₋₃)alkyl, 2-imidazoliny, 2-imidazoliny(C₁₋₃)alkyl, imidazolidinyl, imidazolidinyl(C₁₋₃)alkyl, 2-pyrazoliny, 2-pyrazoliny(C₁₋₃)alkyl, pyrazolidinyl, pyrazolidinyl(C₁₋₃)alkyl, piperidinyl, piperidinyl(C₁₋₃)alkyl, morpholiny, morpholiny(C₁₋₃)alkyl, thiomorpholiny, thiomorpholiny(C₁₋₃)alkyl, piperazinyl, piperazinyl(C₁₋₃)alkyl, [4-(C₁₋₃)alkyl-5-oxo-1,4-dihydropyridazin-1-yl](C₁₋₃)alkyl, piperonyl, (1,3-benzodioxol-5-yl)(C₂₋₃)alkyl, (2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl(C₁₋₃)alkyl, (3,4-dihydro-2*H*-1,5-benzodioxepin-7-yl)carbonyl(C₁₋₃)alkyl, benzyl, phenyl(C₂₋₃)alkyl, phenyl(C₂₋₃)alkynyl, diphenyl(C₁₋₃)alkyl, phenylcarbonyl(C₁₋₃)alkyl, phenylaminocarbonyl(C₁₋₃)alkyl, furyl(C₁₋₃)alkyl, thienyl(C₁₋₃)alkyl, pyrrolyl(C₁₋₃)alkyl, oxazolyl(C₁₋₃)alkyl, thiazolyl(C₁₋₃)alkyl, imidazolyl(C₁₋₃)alkyl, pyrazolyl(C₁₋₃)alkyl, isoxazolyl(C₁₋₃)alkyl, isothiazolyl(C₁₋₃)alkyl, 1,2,3-oxadiazolyl(C₁₋₃)alkyl, 1,2,3-triazolyl(C₁₋₃)alkyl, 1,3,4-thiadiazolyl(C₁₋₃)alkyl, pyridinyl(C₁₋₃)alkyl, pyridazinyl(C₁₋₃)alkyl, pyrimidinyl(C₁₋₃)alkyl, pyrazinyl(C₁₋₃)alkyl, 1,3,5-triazinyl(C₁₋₃)alkyl, indolyl(C₁₋₃)alkyl, benzo[b]furyl(C₁₋₃)alkyl, benzo[b]thienyl(C₁₋₃)alkyl, (R^{1a})₂-N-(C₁₋₃)alkyl and R^{1a}-O-(C₁₋₃)alkyl; wherein pyrrolidinyl, 2-imidazoliny, imidazolidinyl, 2-pyrazoliny, pyrazolidinyl, piperidinyl, morpholiny, thiomorpholiny and piperazinyl are optionally substituted with one to three substituents selected

from oxo; and, wherein phenyl is optionally substituted with one to three substituents independently selected from the group consisting of methyl, ethyl, *n*-propyl, *n*-butyl, methoxy, ethoxy, propoxy, butoxy, chlorine, fluorine, hydroxy and cyano.

5

Most preferably, R¹ is selected from the group consisting of hydrogen, methyl, *n*-propyl, *n*-butyl, allyl, 3,3-dimethyl, cyclopropylmethyl, cyclohexylethyl, 2-(4-ethyl-5-oxo-1,4-dihydropyridazin-1-yl)ethyl, piperonyl, 2-(1,3-benzodioxol-5-yl)ethyl, 2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl, 2-(3,4-dihydro-2*H*-1,5-benzodioxepin-7-yl)-2-oxoethyl, benzyl, phenethyl, phenylpropyl, phenoxyethyl, phenylcarbonylmethyl, phenylcarbonylethyl, phenylaminocarbonylmethyl, thienylmethyl, thienylethyl, imidazolylmethyl, pyridinylmethyl and indolylethyl; wherein phenyl is optionally substituted with one to three substituents independently selected from the group consisting of methoxy, fluorine, hydroxy and cyano.

Embodiments of a compound of Formula (I) include those compounds wherein, preferably, R^{1a} is independently selected from the group consisting of hydrogen, C₁₋₈alkyl and aryl; wherein aryl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy. More preferably, R^{1a} is independently selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *t*-butyl and phenyl; wherein phenyl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, di(C₁₋₆alkyl)amino, halogen, trifluoromethyl and trifluoromethoxy. Most preferably, R^{1a} is independently selected from the group consisting of methyl, ethyl and phenyl.

30

Embodiments of a compound of Formula (I) include those compounds wherein, preferably, R² is selected from the group consisting of phenyl, naphthalenyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl,

isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, indolyl, benzo[b]furyl and benzo[b]thienyl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃alkenyl, 5 C₁₋₃alkoxy, amino, C₁₋₃alkylamino, di(C₁₋₃alkyl)amino, C₁₋₃alkylcarbonyl, C₁₋₃alkylcarbonyloxy, C₁₋₃alkylcarbonylamino, chlorine, fluorine, hydroxy, trifluoromethyl and trifluoromethoxy.

More preferably, R² is selected from the group consisting of phenyl, 10 furyl, thienyl, pyridinyl and benzo[b]furyl optionally substituted with one substituent selected from the group consisting of methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, methylcarbonyl, methylcarbonyloxy, methylcarbonylamino, fluorine, hydroxy, trifluoromethyl and trifluoromethoxy.

15

Most preferably, R² is selected from phenyl optionally substituted with one substituent selected from the group consisting of methoxy and hydroxy.

Embodiments of a compound of Formula (I) include those compounds 20 wherein, preferably, R³ is selected from the group consisting of phenyl, naphthalenyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, indolyl, benzo[b]furyl and benzo[b]thienyl optionally substituted with one or two substituents in 25 addition to the -A-Z moiety independently selected from the group consisting of methyl, ethyl, *n*-propyl, *i*-propyl, allyl, methoxy, ethoxy, amino, C₁₋₃alkylamino, di(C₁₋₃)alkylamino, C₁₋₃alkylcarbonyl, C₁₋₃alkylcarbonyloxy, C₁₋₃alkylcarbonyl, C₁₋₃alkylaminocarbonyl, C₁₋₃alkylcarbonylamino, C₁₋₃alkylthio, C₁₋₃alkylsulfonyl, chloro, fluoro, hydroxy, cyano, trifluoromethyl and trifluoromethoxy; 30 alternatively, when phenyl is substituted with two optional substituents attached to adjacent carbon atoms, the two substituents can together form a single fused moiety; wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-.

More preferably, R³ is phenyl substituted with the moiety -A-Z at the 3 or 4 position.

- 5 Embodiments of a compound of Formula (I) include those compounds wherein, preferably, A is -C(=X)-.

Embodiments of a compound of Formula (I) include those compounds wherein, preferably, Z is -N(R⁵)(R⁶).

10

- An embodiment of a compound of Formula (I) includes those compounds wherein, preferably, R⁴ is selected from the group consisting of C₁₋₈alkyl (optionally substituted with one to three halogen substituents), C₂₋₈alkenyl, aryl and aryl(C₁₋₈)alkyl; wherein aryl is optionally substituted with one to two substituents independently selected from the group consisting of C₁₋₈alkyl, -OCH₂O-, -O(CH₂)₂O- and halogen.
- 15

- More preferably, R⁴ is selected from the group consisting of C₁₋₃alkyl (optionally substituted with one or three fluorine substituents), C₂₋₄alkenyl, phenyl and benzyl; wherein phenyl is optionally substituted with one to two substituents independently selected from the group consisting of C₁₋₃alkyl, -OCH₂O-, -O(CH₂)₂O- and fluorine.
- 20

- Most preferably, R⁴ is selected from the group consisting of methyl, ethyl, 3-methyl, phenyl and benzyl; wherein phenyl is optionally substituted with one substituent selected from the group consisting of methyl and fluorine.
- 25

- An embodiment of a compound of Formula (I) includes those compounds wherein, preferably, R⁵ and R⁶ are independently selected from the group consisting of hydrogen, C₁₋₄alkyl, fluoro(C₁₋₃)alkyl, trifluoro(C₁₋₃)alkyl, C₁₋₃alkoxy(C₁₋₃)alkyl, C₂₋₅alkenyl, cyclopropyl, cyclopropyl(C₁₋₃)alkyl, cyclopentyl, cyclopentyl(C₁₋₃)alkyl, cyclohexyl, cyclohexyl(C₁₋₃)alkyl, pyrrolidiny, pyrrolidinyl(C₁₋₃)alkyl, 1,3-dioxolanyl, 1,3-dioxolanyl(C₁₋₃)alkyl, 2-imidazoliny,
- 30

- 2-imidazolinyl(C₁₋₃)alkyl, imidazolidinyl, imidazolidinyl(C₁₋₃)alkyl, 2-pyrazolinyl, 2-pyrazolinyl(C₁₋₃)alkyl, pyrazolidinyl(C₁₋₃)alkyl, piperidinyl, piperidinyl(C₁₋₃)alkyl, morpholinyl, morpholinyl(C₁₋₃)alkyl, thiomorpholinyl, thiomorpholinyl(C₁₋₃)alkyl, piperazinyl, piperazinyl(C₁₋₃)alkyl, piperonyl, phenyl, benzyl, phenyl(C₂₋₃)alkyl,
- 5 furyl, furyl(C₁₋₃)alkyl, thienyl, thienyl(C₁₋₃)alkyl, pyrrolyl(C₁₋₃)alkyl, oxazolyl, oxazolyl(C₁₋₃)alkyl, thiazolyl, thiazolyl(C₁₋₃)alkyl, imidazolyl, imidazolyl(C₁₋₃)alkyl, pyrazolyl, pyrazolyl(C₁₋₃)alkyl, isoxazolyl, isoxazolyl(C₁₋₃)alkyl, isothiazolyl, isothiazolyl(C₁₋₃)alkyl, 1,2,3-oxadiazolyl, 1,2,3-oxadiazolyl(C₁₋₃)alkyl, 1,2,3-triazolyl, 1,2,3-triazolyl(C₁₋₃)alkyl, 1,3,4-thiadiazolyl,
- 10 1,3,4-thiadiazolyl(C₁₋₃)alkyl, pyridinyl, pyridinyl(C₁₋₃)alkyl, pyridazinyl, pyridazinyl(C₁₋₃)alkyl, pyrimidinyl, pyrimidinyl(C₁₋₃)alkyl, pyrazinyl, pyrazinyl(C₁₋₃)alkyl, 1,3,5-triazinyl, 1,3,5-triazinyl(C₁₋₃)alkyl, indolyl(C₁₋₃)alkyl, benzo[b]furyl, benzo[b]furyl(C₁₋₃)alkyl, benzo[b]thienyl, benzo[b]thienyl(C₁₋₃)alkyl, benzimidazolyl, benzimidazolyl(C₁₋₃)alkyl,
- 15 amino(C₁₋₃)alkyl, C₁₋₃alkylamino(C₁₋₃)alkyl, di(C₁₋₃)alkylamino(C₁₋₃)alkyl, aminoimino, hydroxy(C₁₋₃)alkyl and trifluoro(C₁₋₄)alkoxy; wherein pyrrolidinyl, 1,3-dioxolanyl, 2-imidazolinyl, imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl are optionally substituted with one to three substituents independently selected from the group consisting
- 20 of C₁₋₄alkyl and oxo; and, wherein phenyl is optionally substituted with one to four substituents independently selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkoxy, -OCH₂O-, -O(CH₂)₂O-, halogen, hydroxy and cyano; alternatively, R⁵ and R⁶ may, together with the nitrogen to which they are attached, form a fused heterocyclyl moiety selected from the group consisting of pyrrolidinyl,
- 25 imidazolidinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and piperazinyl optionally substituted with one to four substituents independently selected from C₁₋₄alkyl.


More preferably, R⁵ and R⁶ are independently selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, *t*-butyl, fluoro(C₁₋₃)alkyl, methoxy(C₁₋₃)alkyl, methallyl, cyclopropyl, cyclohexyl, phenyl, thiazolyl, imidazolyl(C₁₋₃)alkyl, benzimidazolyl(C₁₋₃)alkyl, dimethylamino(C₁₋₃)alkyl and hydroxy(C₁₋₃)alkyl; wherein phenyl is optionally substituted with one to three

substituents selected from fluorine; alternatively, R^5 and R^6 may, together with the nitrogen to which they are attached, form a fused heterocyclyl moiety selected from the group consisting of pyrrolidinyl, piperidinyl and morpholinyl optionally substituted with one to four substituents independently selected from the group consisting of methyl, ethyl, *n*-propyl and *n*-butyl.

- Most preferably, R^5 and R^6 are independently selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, *t*-butyl, 2-fluoroethyl, methoxyethyl, methallyl, cyclopropyl, cyclohexyl, phenyl, thiazolyl, 2-(2-imidazolyl)ethyl, benzimidazolylmethyl, dimethylaminopropyl and hydroxyethyl; wherein phenyl is optionally substituted with fluorine; alternatively, R^5 and R^6 may, together with the nitrogen to which they are attached, form a fused heterocyclyl moiety selected from the group consisting of pyrrolidinyl, piperidinyl and morpholinyl; wherein piperidinyl is substituted with two or four substituents selected from methyl.

- Table 1 lists compounds exemplified in the present invention of the formula:

Table 1



- wherein the moiety $-C(=X)-$ is substituted on phenyl at the 3 or 4 position and R^1 , $-C(=X)-$ and Z are dependently selected from the group consisting of:

Ex #	R^1	$-C(=X)-$	Z
1	methyl	$-4-C(=O)-$	N,N-diethylamino;

2	H	-4-C(=O)-	N,N-diethylamino;
5	allyl	-4-C(=O)-	N,N-diethylamino;
7	2-(4-fluorophenyl)ethyl	-4-C(=O)-	N,N-diethylamino;
8	2-(2-thienyl)ethyl	-4-C(=O)-	N,N-diethylamino;
9	2-(3-indolyl)ethyl	-4-C(=O)-	N,N-diethylamino;
10	2-cyclohexylethyl	-4-C(=O)-	N,N-diethylamino;
11	2-phenoxyethyl	-4-C(=O)-	N,N-diethylamino;
12	2-(4-ethyl-5-oxo-1,4-dihydropyridazin-1-yl)ethyl	-4-C(=O)-	N,N-diethylamino;
13	2-phenyl-2-oxoethyl	-4-C(=O)-	N,N-diethylamino;
14	2-(4-methoxyphenyl)-2-oxoethyl	-4-C(=O)-	N,N-diethylamino;
15	2-(3-cyanophenyl)-2-oxoethyl	-4-C(=O)-	N,N-diethylamino;
16	2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl	-4-C(=O)-	N,N-diethylamino;
17	2-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-2-oxoethyl	-4-C(=O)-	N,N-diethylamino;
18	propyl	-4-C(=O)-	N,N-diethylamino;
19	2-phenylethyl	-4-C(=O)-	N,N-diethylamino;
20	piperonyl	-4-C(=O)-	N,N-diethylamino;
21	3-phenylpropyl	-4-C(=O)-	N,N-diethylamino;
22	methyl	-3-C(=O)-	N-methyl-N-(3-fluorophenyl)amino;
25	2-phenylethyl	-4-C(=S)-	N,N-diethylamino;
26	2-phenylethyl	-4-C(=O)-	N-ethylamino;
29	2-phenylethyl	-4-C(=O)-	amino;
30	2-phenylethyl	-4-C(=O)-	4-morpholinyl;
31	2-phenylethyl	-4-C(=O)-	N,N-diisopropylamino;
32	2-phenylethyl	-4-C(=O)-	N,N-bis(methoxyethyl)amino;
33	2-phenylethyl	-4-C(=O)-	1-pyrrolidinyl;
34	2-phenylethyl	-4-C(=O)-	2,6-dimethyl-1-piperidinyl;
35	2-phenylethyl	-4-C(=O)-	N-ethyl-N-(methylallyl)amino;


36	2-phenylethyl	-4-C(=O)-	N,N-dipropylamino;
37	2-phenylethyl	-4-C(=O)-	N- <i>t</i> -butylamino;
38	2-phenylethyl	-4-C(=O)-	N-(2-fluoroethyl)amino;
39	2-phenylethyl	-4-C(=O)-	N-(2-thiazolyl)amino;
40	2-phenylethyl	-4-C(=O)-	N-(2-methoxyethyl)amino;
41	2-phenylethyl	-4-C(=O)-	N-(1 <i>H</i> -benzimidazol-2-ylmethyl)amino;
42	2-phenylethyl	-4-C(=O)-	N-cyclohexylamino;
43	2-phenylethyl	-4-C(=O)-	N-phenylamino;
44	2-phenylethyl	-4-C(=O)-	N-[2-(2-imidazolyl)ethyl]amino;
45	2-phenylethyl	-4-C(=O)-	N-cyclopropylamino;
46	2-phenylethyl	-4-C(=O)-	N,N-(dimethylaminopropyl)amino;
47	2-phenylethyl	-4-C(=O)-	N-ethyl-N-(hydroxyethyl)amino;
48	2-(1,3-benzodioxol-5-yl)ethyl	-4-C(=O)-	N-ethylamino;
49	2-(1,3-benzodioxol-5-yl)ethyl	-4-C(=O)-	N,N-diethylamino;
50	methyl	-4-C(=O)-	N-ethylamino;
51	H	-4-C(=O)-	N-ethylamino;
52	allyl	-4-C(=O)-	N-ethylamino;
53	2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N,N-diethylamino;
54	2-(4-methoxyphenyl)ethyl	-4-C(=O)-	4-morpholinyl;
55	2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N-ethylamino;
56	2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N,N-bis(2-methoxyethyl)amino;
57	2-(4-methoxyphenyl)ethyl	-4-C(=O)-	1-pyrrolidinyl;
58	2-(4-methoxyphenyl)ethyl	-4-C(=O)-	2,6-dimethyl-1-piperidinyl;
59	2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N-ethyl-N-(methylallyl)amino;
60	2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N,N-(di- <i>n</i> -propyl)amino;
61	2-(4-methoxyphenyl)ethyl	-4-C(=O)-	2,2,6,6-tetramethyl-1-piperidinyl;
62	2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N,N-(di-2-propyl)amino;

69	2-(4-hydroxyphenyl)ethyl	-4-C(=O)-	N-ethylamino; and,
70	2-(4-hydroxyphenyl)ethyl	-4-C(=O)-	N,N-diethylamino;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

- 5 Table 2 lists compounds exemplified in the present invention of the formula:

Table 2



wherein R¹, R², R⁵ and R⁶ are dependently selected from the group consisting of:

Ex #	R¹	R²	(R⁵)(R⁶)
63	methyl	4-MeOPh	(H)(Et);
64	H	4-HOPh	(H)(Et) ;
65	methyl	4-MeOPh	Et₂;
66	H	4-HOPh	Et₂;
67	2-(4-MeOPh)ethyl	4-MeOPh	Et₂; and,
68	2-(4-HOPh)ethyl	4-HOPh	Et₂;

10

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

- Instant compounds of the invention may also be present in the form of a
 15 pharmaceutically acceptable salt. The pharmaceutically acceptable salt

generally takes a form in which the basic nitrogen is protonated with an inorganic or organic acid. Representative organic or inorganic acids include hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharic or trifluoroacetic.

It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth herein.

The compounds of this invention are chiral and, thus, may exist as enantiomers. In addition, the compounds may exist as diastereomers. It is to be understood that all such enantiomers and diastereomers, as well as all mixtures thereof, are encompassed within the scope of the present invention.

Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention.

In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.

The present invention also contemplates a pharmaceutical composition comprising a combination of a δ -opioid or μ -opioid receptor modulator compound of Formula (I) and a μ -opioid receptor modulator compound known to those skilled in the art or a δ -opioid or μ -opioid receptor modulator

compound of Formula (I) wherein the combination has a synergistic therapeutic effect.

Suitable μ -opioid receptor modulator compounds known to those skilled in the art for use in such a combination include, without limitation, the

5 compounds alfentanil, allylprodine, alphaprodine, anileridine, bezitramide, buprenorphine, clonitazene, cyclazocine, dextromoramide, dihydrocodeine, dihydromorphine, ethoheptazine, ethylmorphine, etonitazene, fentanyl, heroin, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, lofentanil, meperidine, meptazinol, metazocine, methadone,

10 morphine, nalbuphine, norlevorphanol, normethadone, nalorphine, normorphine, opium, oxycodone, oxymorphone, phenazocine, piritramide, propiram, propoxyphene, sufentanil, tramadol and diastereomers, salts, complexes and mixtures thereof of any of the foregoing.

15 The terms used in describing the invention are commonly used and known to those skilled in the art. However, the terms that could have other meanings are hereinafter defined. These definitions apply to the terms as they are used throughout this specification, unless otherwise limited in specific instances, either individually or as part of a larger group.

20 An "independently" selected substituent refers to a group of substituents, wherein the substituents may be different. Therefore, designated numbers of carbon atoms (e.g., C₁-C₈) shall refer independently to the number of carbon atoms in an alkyl or cycloalkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.

25 The term "alkyl" refers to straight and branched-chain alkyl radical groups with 1 to 8 carbon atoms or any number within this range. The terms "alkenyl" and "alkynyl" refer to radical groups having straight and branched chains with 2 to 8 carbon atoms or any number within this range. For alkenyl chains, one double bond is formed between adjacent members of a two or

30 three carbon chain and one or two double bonds are formed between adjacent

members of a four to eight carbon chain. For alkynyl chains, one triple bond is formed between adjacent members of a two or three carbon chain and one or two triple bonds are formed between adjacent members of a four to eight carbon chain. Correspondingly, the terms "alkylene," "alkenylene" and

5 "alkynylene" refer to alkyl, alkenyl and alkynyl linking groups wherein alkyl, alkenyl and alkynyl are as defined supra. Preferably, alkenylene and alkynylene linking group chains have at least one saturated carbon atom on each side of the unsaturated bond. More preferably, when an aryl or

10 heteroaryl substituent is attached to the terminal carbon of an alkenylene or alkynylene linking group, at least one saturated carbon atom is between the unsaturated bond and the substituent. The term "alkoxy" refers to O-alkyl groups wherein alkyl is as defined supra.

Whenever the term "alkyl" appears in the name of a substituent (e.g.,

15 hydroxy(C₁₋₆)alkyl) it shall be interpreted as including those limitations given above for "alkyl." Designated numbers of carbon atoms (e.g., C₁₋₆) shall refer independently to the number of carbon atoms in an alkyl or cycloalkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.

20

The term "cycloalkyl" refers to branched or unbranched cyclic aliphatic hydrocarbon chains of three to seven carbon atom members. Examples of such cyclic alkyl rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

25 The term "heterocyclyl" refers to a nonaromatic cyclic ring of five to seven members in which one to four members are nitrogen or a nonaromatic cyclic ring of five to seven members in which zero, one or two members are nitrogen and one member is oxygen or sulfur; and in which,

- a) optionally, the ring contains zero, one or two unsaturated bonds;
- 30 b) optionally, up to three carbon members adjacent to nitrogen members may be oxo substituted.

Optionally, the heterocyclyl ring is fused:

- a) to a benzene ring;
- b) to a 5 or 6 membered heteroaryl containing one of O, S or N and, optionally, one additional nitrogen;
- 5 c) to a 5 to 7 membered alicyclic ring;
- d) to a 5 to 7 membered heterocyclyl ring of the same definition as above but absent the option of a further fused ring.

For instant compounds of the invention, the carbon atom ring members
10 that form the heterocyclyl ring are fully saturated. Other compounds of the invention may have a partially saturated heterocyclyl ring. Preferred partially unsaturated heterocyclyl rings may have one or two double bonds. Such compounds are not considered to be fully aromatic and are not referred to as heteroaryl compounds. Therefore, a five member heterocyclyl ring may
15 optionally have a double bond formed in the ring between adjacent ring members; a six or seven member heterocyclyl ring may have two double bonds formed in the ring between adjacent ring members.

The term aryl refers to a single aromatic ring of six carbon members or a
20 bicyclic aromatic ring of ten carbon members. Examples of such aryl rings include phenyl and naphthyl.

The term heteroaryl refers to an aromatic ring of five or six members wherein the ring has at least one heteroatom member. Suitable heteroatoms include nitrogen, oxygen or sulfur. In the case of five-membered rings, the
25 heteroaryl ring contains one member of nitrogen, oxygen or sulfur and, in addition, may contain up to two additional nitrogens. In the case of six-membered rings, the heteroaryl ring may contain from one to three nitrogen atoms. For the case wherein the six member ring has three nitrogens, at most two nitrogen atoms are adjacent.

30 The terms "halo₁₋₃(C₁₋₈)alkyl," "cycloalkyl(C₁₋₈)alkyl" or "hydroxy(C₁₋₆)alkyl" refer to an alkylene group substituted at the terminal carbon with a halo,

cycloalkyl or hydroxy group, respectively. Similarly, the term "C₁₋₈alkoxy(C₁₋₈)alkenyl" or "C₁₋₈alkoxy(C₁₋₈)alkynyl" refers to an alkenylene or alkynylene group substituted at the terminal carbon with an alkoxy group. The term "carbonyl" refers to the linking group -C=O-. Furthermore, the term

5 "methylenedioxy" refers to the substituent moiety -OCH₂O-, the term "ethylenedioxy" refers to the substituent moiety -O(CH₂)₂O- and the term "trimethylenedioxy" refers to the substituent moiety -O(CH₂)₃O-. The term "hydroxy" refers to the group -OH and the term "oxo" refers to the group =O. The term "halo" or "halogen" refers to the group iodine, bromine, chlorine and

10 fluorine.

Where the compounds according to this invention are chiral, they may accordingly exist as enantiomers. In addition, the compounds may exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

15 The terms used in describing the invention are commonly used and known to those skilled in the art. As used herein, the following abbreviations have the indicated meanings:

	DCE	1,2-dichloroethane
	Et ₂ O	Diethyl ether
20	EtOH	Ethanol
	h	Hour
	K ₂ CO ₃	Potassium carbonate
	MeOH	Methanol
	NaBH ₄	Sodium borohydride
25	NaBH(OAc) ₃	Sodium triacetoxymborohydride
	min	Minute
	2-PrOH	2-Propanol
	rt	Room temperature
	TiCl ₄	Titanium(IV) tetrachloride

30 General Synthetic Methods

Representative compounds of the present invention can be synthesized

in accordance with the general synthetic methods described below and are illustrated in the schemes that follows. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.

Scheme 1 describes a general scheme for the preparation of certain target 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives of the invention using synthetic methods to prepare intermediate compounds also intended to be within the scope of the present invention.

A Suzuki reaction is used to couple a boronic acid Compound **1a** with an iodinated Compound **1b** in the presence of carbon monoxide to produce an intermediate Compound **1c**. Alternatively, Compound **1b** may also be substituted with bromine or OTF (trifluoromethylsulfonyloxy) in place of iodine. For Compound **1a** and Compound **1b**, the R² and R³ substituents and -A-Z moiety may be varied by using appropriate starting materials or may be added in later steps.


For example, the -A- portion of the -A-Z moiety may be varied using -C(=O)- or -SO₂- (more preferably, -C(=O)-) and the -Z- portion of the -A-Z moiety may be varied using -OH, -O(R⁴) or -N(R⁵)(R⁶) (more preferably, -O(R⁴) or -N(R⁵)(R⁶)) to produce other intermediate compounds of the present invention. Similarly, target compounds wherein Z is -O(R⁴) and R⁴ is hydrogen may be conveniently produced by conventional hydrolysis of the Z is -N(R⁵)(R⁶) group; furthermore, other compounds wherein Z is -O(R⁴) and R⁴ is hydrogen may be esterified by conventional methods to produce other target compounds wherein R⁴ is C₁₋₈alkyl.

A Robinson-Schöpf condensation is used to prepare tropinone intermediate Compounds **1e** bearing an R¹ substituent on nitrogen by mixing an R¹ substituted amine Compound **1e** with a succinaldehyde precursor such

as 2,5-dimethoxytetrahydrofuran and acetonedicarboxylic acid. For a Compound **1e**, the R¹ substituent may be varied by using appropriate starting materials or may be added in later steps.

- 5 Compound **1c** and Compound **1e** may be coupled using a titanium mediated "McMurray" reaction to produce a target Compound **1f**.

Scheme 1



- 10 Scheme 2 describes another general scheme for the preparation of certain 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives.


As shown below in Scheme 2, the intermediate Compound **1c** may be coupled with an 8-methyl-8-azabicyclo[3:2:1]octanone compound using
 15 titanium mediated coupling to produce an intermediate Compound **2a**.

The intermediate Compound **2a** may be treated with 2,2,2-trichloroethyl chloroformate followed by reflux with zinc powder in MeOH to obtain the N-demethylated Compound **2b**. Compound **2c** is produced by alkylation of
 20 Compound **2b** with an alkyl halide or reductive alkylation with sodium

triacetoxyborohydride and a carbonyl compound.

As desired, the identity of the -A-Z moiety may be varied by conversion of one -A-Z moiety to another. For example, an -A-Z moiety where the -A-
 5 portion is -C(=O)- and the -Z- portion is -O(R⁴), the -Z- portion may be hydrolyzed to the acid, wherein -O(R⁴) becomes -OH. Subsequently, the resulting carboxyl group may be converted to the desired amide; and, conversely, an amide group may be hydrolyzed to an acid.


Scheme 2



10

As shown in Scheme 3, a Compound 3a wherein X is O may also be further treated with a suitable thionating agent such as P₂S₅ or Lawesson's Reagent to prepare a Compound 3b wherein X is S.

Scheme 3



The compounds of the present invention may be used to treat mild to
5 moderately severe pain in warm-blooded animals such as humans by
administration of an analgesically effective dose. The dosage range would be
from about 0.01 mg to about 15,000 mg, in particular from about 0.1 mg to
about 3500 mg or, more particularly from about 0.1 mg to about 1000 mg of
active ingredient in a regimen of about 1 to 4 times per day for an average (70
10 kg) human; although, it is apparent to one skilled in the art that the
therapeutically effective amount for active compounds of the invention will vary
as will the types of pain being treated.

Examples of pain intended to be within the scope of the present
15 invention include, but are not limited to, centrally mediated pain, peripherally
mediated pain, structural or soft tissue injury related pain, progressive disease
related pain, neuropathic pain and acute pain such as caused by acute injury,
trauma or surgery and chronic pain such as caused by neuropathic conditions,
diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia,
20 post-stroke pain syndromes or cluster or migraine headaches.

In regard to the use of the present compounds as immunosuppressants,
antiinflammatory agents, agents for the treatment of neurological and
psychiatric conditions, medicaments for drug and alcohol abuse, agents for
25 treating gastritis and diarrhea, cardiovascular agents and agents for the
treatment of respiratory diseases, a therapeutically effective dose can be
determined by persons skilled in the art by the use of established animal

models. Such a dose would likely fall in the range of from about 0.01 mg to about 15,000 mg of active ingredient administered 1 to 4 times per day for an average (70 kg) human.

5 Pharmaceutical compositions of the invention comprise the formula (I) compounds as defined above, particularly in admixture with a pharmaceutically acceptable carrier. Illustrative of the invention, therefore, is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compounds described above. Another illustration of the invention is a
10 pharmaceutical composition made by mixing any of the compounds described above and a pharmaceutically acceptable carrier. A further illustration of the invention is a process for making a pharmaceutical composition comprising mixing any of the compounds described above and a pharmaceutically acceptable carrier.

15

 To prepare the pharmaceutical compositions of this invention, one or more compounds of the invention or salt thereof, as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide
20 variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols,
25 flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral
30 dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding

solubility or for preservation, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful
5 and the like, an amount of the active ingredient necessary to deliver an effective dose as described above.

The term "subject" as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment,
10 observation or experiment.

The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by
15 a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

Specific Synthetic Methods

20 Specific compounds which are representative of this invention may be prepared as per the following examples offered by way of illustration and not by way of limitation. For the sake of clarity, bracketed numbers following compound names indicate the stoichiometric salt associated with the compound, which is further exemplified by the calculated analytical data. Also,
25 examples specifically used to prepare intermediates for the further synthesis of compounds of the invention are designated by "Procedure." As well, instant compounds may also be used as starting materials in subsequent examples to produce additional compounds of the present invention. No attempt has been made to optimize the yields obtained in any of the reactions. One skilled in the
30 art would know how to increase such yields through routine variations in reaction times, temperatures, solvents and/or reagents.

Procedure A

N,N-Diethyl-4-benzoylbenzamide

A solution of 25 g (110 mmol) 4-benzoylbenzoic acid [611-95-0] and 20 mL SOCl₂ was allowed to reflux for 2 h then allowed to cool. The excess SOCl₂ was evaporated off and the resulting clear oil was dissolved in 10 mL CH₂Cl₂ then slowly added to 12 mL (116 mmol) diethylamine in a mixture of 10 mL 3N NaOH and 50 mL CH₂Cl₂. The mixture was allowed to stir for 30 min then partitioned between H₂O and CH₂Cl₂. The organic layer was washed with brine, dried over K₂CO₃, filtered and concentrated. The product precipitated from EtOAc/hexane to give 29.6 g (105 mmol) white crystals. MS *m/z* (MH⁺) 282.

Example 1**N,N-Diethyl-4-[(8-methyl-8-azabicyclo[3.2.1]****oct-3-ylidene)phenylmethyl]benzamide Hydrochloride [1:1]**

A 100 mL dry THF slurry of 18.6 g (284 mmol) zinc powder and 15.6 mL (142 mmol) TiCl₄ was stirred and allowed to reflux for 2 h under Ar. The reaction was allowed to cool then a 20 mL THF solution of 10 g (35.5 mmol) N,N-diethyl-4-benzoylbenzamide and 5 g (35.5 mmol) tropinone was added slowly. Once the addition was complete, the reaction was allowed to reflux for 3 h, cooled, then quenched with 10% K₂CO₃ in H₂O. The resulting slurry was partitioned between water and Et₂O. The organic fraction was washed with brine, dried over MgSO₄, filtered, and concentrated. The remaining yellow oil was absorbed onto silica gel then purified by flash chromatography eluted with 10% 0.5 M NH₃ in MeOH 90% CH₂Cl₂ to produce the product N,N-diethyl-4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide (4.27g, 11 mmol). The HCl salt was precipitated from Et₂O after the addition of ethereal HCl; mp 145-147°C. MS *m/z* (MH⁺) 389. ¹H NMR 300 MHz (DMSO-d₆) δ 7.2-7.45 (m, 9H), 3.8-3.9 (m, 2H), 3.15-3.25 (m, 2H), 2.75-2.95 (m, 4H), 2.65 (s, 3H), 2.25-2.4 (m, 2H), 2.15-2.25 (m, 2H), 1.75-1.9 (m, 2H), 0.95-1.2 (m, 6H). Anal calc C₂₆H₃₂N₂O·HCl (3%H₂O): C, 71.21; H, 7.93; N, 6.39. Found: C, 71.16; H, 7.95; N, 6.27.

Example 2**N,N-Diethyl-4-[(8-azabicyclo[3.2.1]****oct-3-ylidene)phenylmethyl]benzamide Hydrochloride [1:1]**

A 100 mL benzene suspension of 3.1 g (5.6 mmol) N,N-diethyl-4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide, 3.45 g (25 mmol) K_2CO_3 , and 1.5 mL (10 mmol) 2,2,2-trichloroethyl chloroformate was allowed to reflux for 2 h. The reaction was cooled, filtered, and the solvent evaporated. The residual oil was dissolved in MeOH then stirred at reflux with 2.6 g (40 mmol) zinc powder for 1 h. After cooling, the reaction was filtered through celite and partitioned between 3N NaOH and CH_2Cl_2 . The organic layer was washed with brine, dried over K_2CO_3 , filtered, and concentrated (2.1 g, 5.6 mmol). The resulting clear oil was dissolved in Et_2O , filtered, and the product precipitated after the addition of ethereal HCl; mp 128-132°C. MS m/z (MH^+) 375. 1H NMR 300 MHz ($DMSO-d_6$) δ 7.15-7.4 (m, 9H), 3.9-4.0 (m, 2H), 3.15-3.3 (m, 2H), 2.55-2.65 (m, 2H), 2.25-2.35 (m, 4H), 1.9-2.0 (m, 2H), 1.75-1.85 (m, 2H), 1.0-1.2 (m, 6H). Anal calc $C_{25}H_{30}N_2O \cdot HCl$ (3% H_2O): C, 70.89; H, 7.71; N, 6.61. Found: C, 70.52; H, 7.41; N, 6.24.

Example 3**(+)-N,N-Diethyl-4-[[[(1R,5S)-8-azabicyclo[3.2.1]****oct-3-ylidene]phenylmethyl]benzamide Fumarate [1:1]**

N,N-Diethyl-4-[(8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide was chromatographed on a CHIRALPAK® AS™ eluting with 90:9.9:0.1 acetonitrile:2-propanol:diethylamine. The first enantiomer to elute was converted to its fumarate salt in 2-PrOH. $[\alpha]_D^{25} = +29^\circ$. MS m/z (MH^+) 375.

Example 4**(-)-N,N-Diethyl-4-[[[(1R,5S)-8-azabicyclo[3.2.1]****oct-3-ylidene]phenylmethyl]benzamide Fumarate [1:1]**

The second enantiomer to elute in the chromatography from the foregoing example was collected. $[\alpha]_D^{25} = -22^\circ$. MS m/z (MH^+) 375.

Example 5**N,N-Diethyl-4-[(8-allyl-8-azabicyclo[3.2.1]****oct-3-ylidene)phenylmethyl]benzamide Hydrochloride [1:1]**

A 20 mL acetonitrile suspension of 0.4 g (1.0 mmol) N,N-diethyl-4-[(8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide, 0.4 g (3.0 mmol) K_2CO_3 , and 0.09 mL allyl bromide was allowed to stir for 3 h. The reaction was filtered and concentrated. The remaining oil was absorbed onto silica gel then purified by flash chromatography eluted with 5% 0.5 M NH_3 in MeOH 95% CH_2Cl_2 . The pure product (0.2 g, 0.4 mmol) was taken up in Et_2O , filtered, and precipitated after the addition of ethereal HCl. MS m/z (MH^+) 415. 1H NMR 300 MHz ($DMSO-d_6$) δ 7.15-7.45 (m, 9H), 5.95-6.10 (m, 1H), 5.4-5.55 (m, 2H), 3.85-3.95 (m, 2H), 3.55-3.65 (t, 2H), 3.35-3.45 (m, 2H), 3.1-3.25 (m, 2H), 2.75-2.85 (t, 2H), 2.2-2.3 (m, 2H), 2.1-2.25 (m, 2H), 1.75-1.9 (m, 2H), 1.0-1.2 (m, 6H).

Example 6**(-)-N,N-Diethyl-4-[(1R,5S)-8-allyl-8-azabicyclo[3.2.1]****oct-3-ylidene]phenylmethyl]benzamide Hydrochloride**

Following the protocol for Example 5 and substituting (+)-N,N-diethyl-4-[[[(1R,5S)-8-azabicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzamide for N,N-diethyl-4-[(8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide the title compound was obtained: MS m/z (MH^+) 415. $[\alpha]_D^{25} = -3.8^\circ$. 1H NMR 300 MHz ($DMSO-d_6$) δ 7.15-7.45 (m, 9H), 5.95-6.10 (m, 1H), 5.4-5.55 (m, 2H), 3.85-3.95 (m, 2H), 3.55-3.65 (t, 2H), 3.35-3.45 (m, 2H), 3.1-3.25 (m, 2H), 2.75-2.85 (t, 2H), 2.2-2.3 (m, 2H), 2.1-2.25 (m, 2H), 1.75-1.9 (m, 2H), 1.0-1.2 (m, 6H).

Examples 7-17**N,N-Diethyl-4-[(8-R¹-8-azabicyclo[3.2.1]****oct-3-ylidene)phenylmethyl]benzamides**

Following the procedure of Example 5 and substituting the appropriate alkyl bromide for allyl bromide the following compounds were prepared:

Ex#	Alkyl bromide	R ¹	MS <i>m/z</i> (MH ⁺)
7	2-(4-fluorophenyl)ethyl bromide	2-(4-fluorophenyl)ethyl	497
8	2-(2-thienyl)ethyl bromide	2-(2-thienyl)ethyl	485
9	3-(2-bromoethyl)indole	2-(3-indolyl)ethyl	518
10	1-bromo-2-cyclohexylethane	2-cyclohexylethyl	485
11	2-phenoxyethyl bromide	2-phenoxyethyl	495
12	1-(bromoethyl)-4-ethyl-1,4-dihydrotetrazol-5-one	2-(4-ethyl-5-oxo-1,4-dihydrotetrazol-1-yl)ethyl	515
13	2-bromo-1-phenylethanone	phenylcarbonylmethyl	493
14	2-bromo-1-(4-methoxyphenyl)ethanone	(4-methoxyphenyl)carbonylmethyl	523
15	2-bromo-1-(3-cyanophenyl)ethanone	(3-cyanophenyl)carbonylmethyl	518
16	2-bromo-1-[3,4-(ethylenedioxy)phenyl]ethanone	3,4-(ethylenedioxyphenyl)carbonylmethyl	551
17	2-bromo-1-[3,4-(trimethylenedioxy)phenyl]ethanone	3,4-(trimethylenedioxyphenyl)carbonylmethyl	565

Example 18

N,N-Diethyl-4-[(8-propyl-8-azabicyclo[3.2.1]

oct-3-ylidene)phenylmethyl]benzamide Hydrochloride [1:1]

- 5 A slurry of 0.4 g (1.0 mmol) N,N-diethyl-4-[(8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide, 0.11 mL (1.5 mmol) propionaldehyde, 0.1 mL (1.7 mmol) HOAc, and 0.5 g (2.3 mmol) NaBH(OAc)₃ in 20 mL DCE was allowed to stir for 16 h. The reaction was made strongly basic with 3N NaOH and diluted with CH₂Cl₂. The organic layer was separated, washed with brine,
- 10 dried over K₂CO₃, filtered, and concentrated. The remaining oil was absorbed onto silica gel and purified by flash chromatography eluted with 5% 0.5 M NH₃ in MeOH 95% CH₂Cl₂. The pure product (0.25 g, 0.6 mmol) was taken up in Et₂O, filtered, and precipitated after the addition of ethereal HCl; mp 184-184°C. MS *m/z* (MH⁺) 417. ¹H NMR 300 MHz (CD₃OD) δ 7.2-7.45 (m, 9H),
- 15 3.95-4.05 (m, 2H), 3.45-3.6 (m, 2H), 3.2-3.3 (m, 2H), 2.95-3.05 (m, 2H), 2.55-

2.7 (m, 4H), 2.2-2.3 (m, 2H), 1.95-2.05 (m, 2H), 1.7-1.85 (m, 2H), 1.0-1.35 (br m, 9H). Anal calc $C_{28}H_{38}N_2O \cdot HCl \cdot 0.5H_2O$: C, 72.78; H, 8.29; N, 6.06. Found: C, 73.01; H, 7.94; N, 5.85.

5

Examples 19-21

N,N-Diethyl-4-[(8-R¹-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamides

Following the procedure of Example 18 and substituting the appropriate carbonyl compound for propionaldehyde the following compounds were

10 prepared:

Ex#	Carbonyl Compound	R ¹	MS <i>m/z</i> (MH ⁺)
19	phenylacetaldehyde	2-phenylethyl	479
20	piperonal	piperonyl	509
21	hydrocinnamaldehyde	3-phenylpropyl	493

Procedure B**N-(3-Fluorophenyl)-N-methyl-3-benzoylbenzamide**

Following Procedure A with the substitution of 20 g (88 mmol) 3-benzoylbenzoic acid [579-18-0] and 8.5 mL (88 mmol) 3-fluoroaniline for 4-benzoylbenzoic acid and diethyl amine, the product N-(3-fluorophenyl)-3-benzoylbenzamide was generated (28 g, 88 mmol) as a clear oil. The oil was dissolved in 50 mL dry THF to which a 10 mL THF slurry of 2.1 g (90 mmol) NaH was slowly added. The mixture was allowed to stir for 5 min then 5.6 mL (90 mmol) of MeI was added and continued stirring for 16 h. The reaction was carefully quenched with water and partitioned between water and CH₂Cl₂. The organic layer was washed with brine, dried over K₂CO₃, filtered, and concentrated to yield 29.3 g (88 mmol) product. MS *m/z* (MH⁺) 334.

Example 22

N-(3-Fluorophenyl)-N-methyl-3-[(8-methyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide Fumarate [1:1]

Following the procedure of Example 1 with the substitution of N-(3-fluorophenyl)-N-methyl-3-benzoylbenzamide obtained in Procedure B for N,N-

diethyl-4-benzoylbenzamide, the product N-(3-fluorophenyl)-N-methyl-3-[(8-methyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide was produced. The fumarate salt was precipitated from 2-PrOH/hexane, mp 122-125°C. MS m/z (MH^+) 441. 1H NMR 300 MHz (DMSO- d_6) δ 6.85-7.35 (m, 13H), 3.4 (s, 3H), 3.3-3.5 (m, 1H), 3.15-3.2 (m, 1H), 3.4-3.55 (m, 2H), 2.35 (s, 3H), 2.15-2.25 (m, 1H), 2.05-2.15 (m, 1H), 1.9-2.05 (m, 2H), 1.55-1.65 (m, 1H), 1.35-1.55 (br ms, 1H). Anal calc $C_{29}H_{29}FN_2O \cdot C_4H_4O_4$: C, 71.21; H, 5.98; N, 5.03. Found: C, 71.50; H, 6.20; N, 4.92.

10

Example 23

(-)-N,N-Diethyl-4-[[[(1R,5S)-8-phenethyl-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzamide Hydrochloride [1:1]

A suspension of 52 g (0.8 mole) of zinc powder and 800 mL of THF was cooled in an ice bath 44 mL (0.4 mole) of $TiCl_4$ was added dropwise with stirring. The ice bath was removed and the reaction refluxed for 2 h. A solution of 26.45 g (0.094 mole) of N,N-diethyl-4-benzoylbenzamide and 23.9 g (0.094 mole) of 8-phenethyl-8-azabicyclo[3.2.1]octan-3-one, in 100 mL of THF was added dropwise and the reaction was refluxed 4h. After cooling, the reaction mixture was poured into a beaker containing excess K_2CO_3 and ice. The mixture was extracted with ether, washed with brine, dried (K_2CO_3) and concentrated. There was obtained 47 g (~0.1 mol) of crude (\pm)-N,N-diethyl-4-[(8-phenethyl-8-azabicyclo[3:2:1]oct-3-ylidene)phenylmethyl]benzamide as an oil. A sample of the oil and 38.33g (0.1 mole) of (+)-ditoluoyl-D-tartaric acid were combined in 600 mL of acetonitrile. The solid was collected and recrystallized twice from acetonitrile. The solid was collected and partitioned between dilute sodium hydroxide and CH_2Cl_2 . The organic solution was dried (K_2CO_3) and concentrated. The residue was converted to a hydrochloride salt (Et_2O/HCl). It was recrystallized from 2-PrOH to give 5.6g of white solid. Et_2O , filtered, and precipitated after the addition of ethereal HCl; mp 210-211°C. MS m/z (MH^+) 479. 1H NMR 300 MHz ($CDCl_3$) δ 12.6 (s, 1H), 7.2-7.45 (m, 14H), 3.85 (s, 2H), 3.5-3.1 (m, 10H), 2.6 (d, 1H), 2.5 (d, 2H), 2.05 (m, 2H), 1.2 (br. s, 3H), 1.1 (br. s, 3H). $[\alpha]_D^{25} = -3.7^\circ$.

Example 24

(+)-N,N-Diethyl-4-[[[(1S,5R)-8-phenethyl-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzamide Hydrochloride [1:1]

The mother liquors from the foregoing example were concentrated and
 5 partitioned between dilute sodium hydroxide and CH₂Cl₂. The organic solution
 was concentrated (40.5 g, 0.084 mole) and 32.7 g (0.084 mole) of (-)-ditoluoyl-
 L-tartaric acid were combined in 500 mL of acetonitrile. The solid was
 collected and recrystallized twice from acetonitrile. The solid was collected and
 partitioned between dilute sodium hydroxide and CH₂Cl₂. The organic solution
 10 was dried (K₂CO₃) and concentrated. The residue was converted to a
 hydrochloride salt (Et₂O/HCl) and recrystallized from 2-PrOH to give a white
 solid; mp 211-212°C. MS *m/z* (MH⁺) 479. ¹H NMR 300 MHz (CDCl₃) δ 12.6
 (s, 1H), 7.2-7.45 (m, 14H), 3.85 (s, 2H), 3.5-3.1 (m, 10H), 2.6 (d, 1H), 2.5 (d,
 2H), 2.05 (m, 2H), 1.2 (br. s, 3H), 1.1 (br. s, 3H). [α]_D²⁵ = +3.7°.

15

Example 25

(-)-N,N-Diethyl-4-[[8-phenethyl-8-aza(1R, 5S)bicyclo[3:2:1]oct-3-ylidene]phenylmethyl]thiobenzamide

A mixture of 1.48 g (3.1 mmol) of (-)-N,N-diethyl-4-[[8-phenethyl-8-aza(1R,
 20 5S)bicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzamide and 1.87 g of
 Lawesson's reagent was heated at 60°C in 50 mL of benzene for 2 h. The
 resulting mixture was flash chromatographed using 5% MeOH in CH₂Cl₂. MS
m/z (MH⁺) 495. ¹H NMR 300 MHz (CDCl₃) δ 8.2 (m, 2H), 7.3-7.0 (m, 10H), 6.8
 (m, 2H) 4.0 (m, 4H), 3.7-3.2 (m, 10H), 2.7-2.4 (m, 3H), 2.1-1.6 (m, 4H), 1.4 (t,
 25 3H), 1.1 (t, 3H).

Procedure C

Ethyl 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoate

30 After a mixture of 52 g (0.8 mole) of zinc powder and 800 mL of THF was
 cooled in an ice bath 44 mL (0.4 mole) of TiCl₄ was added dropwise with
 stirring. The ice bath was removed and the reaction refluxed for 2 h. A
 solution of 21.5 g (0.094 mole) of ethyl 4-benzoylbenzoate, 23.9 g (0.094 mole)

of 8-phenethyl-8-azabicyclo[3.2.1]octan-3-one, in 100 mL of THF was added dropwise and the reaction was refluxed overnight. After cooling the reaction mixture was poured into a beaker containing K_2CO_3 and ice. Enough K_2CO_3 was added until basic. The solid was filtered off and the organics from the filtrate were separated. The aqueous layer was extracted with Et_2O and the organics were combined, washed with brine and dried over K_2CO_3 . The solvent was evaporated *in vacuo*. The residue was first passed through a flash column, silica gel, (9:1; CH_2Cl_2 :MeOH) then a second column using silica gel with 3:1 hexane:acetone to give 21.8 g of the title compound. MS m/z (MH^+) 452. 1H NMR ($DMSO-d_6$) δ 8.0 (d, 2H); 7.35-7.1 (Ar, 12H); 4.3 (t, 2H); 2.8 (m, 2H); 2.7 (m, 2H); 2.4 (bd, 2H); 2.3-2.2 (m, 3H); 1.9 (m, 2H); 1.6 (m, 3H); 1.3 (q, 3H).

Procedure D

15 **4-[(8-Phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoic Acid**

A mixture of 22 g (0.048 mole) of ethyl 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoate, 86 mL of 3N NaOH and 200 mL of EtOH was refluxed for 1 h. After cooling the mixture was made acidic with conc. HCl. The solvent was decanted away from the gum which formed. The gum was titrated with Et_2O and Et_2O/HCl and was placed into a drying oven overnight at 45°C to yield 19.2 g of 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoic acid; mp. 285-290°C. MS m/z (MH^+) 425. 1H NMR δ 7.9 (d, 2H); 7.4-7.2 (ar, 12H); 3.7 (bs, 2H); 3.0 (bs, 4H); 2.8 (bd, 2H); 2.2 (t, 2H); 2.0 (m, 2H); 1.65 (m, 2H).

Procedure E

30 **4-[(8-Phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoyl Chloride**

A mixture of 6 g (0.014 mole) of 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoic acid, 20 ml of $CHCl_3$ and 3 mL (0.042 mole) of thionyl chloride were refluxed for 1.5 h. The solvent was evaporated *in vacuo* to give 6.2 g of 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-

ylidene)phenylmethyl]benzoyl chloride. MS m/z (MH^+) of CH_3OH quench 437.

Example 26

N-Ethyl-4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide

5 A mixture of 11.4 g (0.14 mole) of ethylamine hydrochloride and 150 mL of 3N NaOH and 100 mL of CH_2Cl_2 were cooled in an ice bath. A solution of 4.7 g (0.015 mole) of 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoyl chloride prepared using Procedure E in 60 mL of
10 CH_2Cl_2 was added. After the addition was complete, the ice bath was removed and the reaction stirred at room temperature for 2 h. The organics were separated off and washed with water, brine and dried (K_2CO_3). The solvent was evaporated *in vacuo* and converted to the HCl salt with Et_2O/HCl to give
15 1.86 g of N-ethyl-4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide; mp 296-298°C (Decomp). MS m/z (MH^+) 451. 1H NMR ($DMSO-d_6$) δ 8.5 (ar, 1H); 7.8 (d, 2H); 7.4-7.1 (ar, 12H); 4.05 (bs, 2H); 3.4-3.2 (m, 3H); 3.1 (s, 3H); 2.9 (d, 2H); 2.4 – 2.1 (m, 4H); 1.8 (m, 2H); 1.1 (t, 3H).

20

Example 27

(-)-4-[[8-Phenethyl-8-aza(1R,5S)bicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzamide

4-[[8-Phenethyl-8-aza(1R,5S)bicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzamide was chromatographed on a CHIRALPAK®
25 Ad™ column eluting with $EtOH + 0.1\%$ dea. The first enantiomer to elute was collected and converted to the hydrochloride with Et_2O/HCl . $[\alpha]_D^{25} = -9.7^\circ$. MS m/z (MH^+) 451. 1H NMR ($DMSO-d_6$) δ 8.5 (ar, 1H); 7.8 (d, 2H); 7.4-7.1 (ar, 12H); 4.05 (bs, 2H); 3.4-3.2 (m, 3H); 3.1 (s, 3H); 2.9 (d, 2H); 2.4 – 2.1 (m, 4H); 1.8 (m, 2H); 1.1 (t, 3H).

30

Example 28

(+)-4-[[8-Phenethyl-8-aza(1S,5R)bicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzamide

The second enantiomer to elute was collected and converted to the hydrochloride with Et₂O/HCl. $[\alpha]_D^{25} = +9.3^\circ$. MS *m/z* (MH⁺) 451. ¹H NMR (DMSO-d₆) δ 8.5 (ar, 1H); 7.8 (d, 2H); 7.4-7.1 (ar, 12H); 4.05 (bs, 2H); 3.4-3.2 (m, 3H); 3.1 (s, 3H); 2.9 (d, 2H); 2.4 –2.1 (m, 4H); 1.8 (m, 2H); 1.1 (t, 3H).

5

Example 29

4-[(8-Phenethyl-8-azabicyclo[3.2.1]

oct-3-ylidene)phenylmethyl]benzamide Hydrochloride [1:1].

A 1.5 g (0.0034 mole) sample of 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoyl chloride was cooled in an ice bath. 30 mL of NH₄OH was added dropwise. The ice bath was removed and the mixture was stirred at room temperature for 2 h. The solid was filtered off and dried. The product was passed through a Biotage Flash 40 L (silica gel, 9:1; CH₂Cl₂:MeOH). Conversion to the HCl salt and recrystallization from EtOH/Et₂O gave 0.45 g of 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide; mp. 210-212°C. MS *m/z* (MH⁺) 423. ¹H NMR (DMSO-d₆) δ 7.95 (s, 1H); 7.9 (d, 2H); 7.4-7.2 (ar, 12H); 4.05 (bs, 1H); 3.6 (q, 2H); 2.9 (d, 2H); 2.4-2.1 (m, 5H); 1.8 (m, 3H); 1.1 (t, 3H).

20

Examples 30-47

N,N-R²,R³-4-[(8-Phenethyl-8-azabicyclo[3.2.1]

oct-3-ylidene)phenylmethyl]benzamides

By the method of Example 26 and substituting the appropriate amine for ethylamine hydrochloride, the title compound was prepared.

25

Ex	Amine	CIMS (MH ⁺)
30	morpholine	493
31	diisopropylamine	506
32	bis(methoxyethyl)amine	538
33	pyrrolidine	477
34	<i>cis</i> -2,6-dimethylpiperidine	519
35	N-ethyl-N-(methylallyl)amine	505
36	dipropylamine	507

37	t-butylamine	479
38	2-fluoroethylamine	469
39	2-aminothiazole	507
40	2-methoxyethylamine	481
41	(1 <i>H</i> -benzimidazol-2-ylmethyl)amine	553
42	cyclohexylamine	505
43	aniline	499
44	histamine	517
45	cyclopropylamine	463
46	N,N-(dimethylaminopropyl)amine	508
47	N-ethyl-N-(hydroxyethyl)amine	495

Procedure F

8-(2-Benzo[1,3]dioxol-5-ylethyl)-8-azabicyclo[3.2.1]octan-3-one

A 41 g sample of 2,5-dimethoxytetrahydrofuran (0.32 ml) was suspended in
 5 300 mL of H₂O and 40 mL of *o*-phosphoric acid was added. The mixture was
 stirred for 3 h then brought to pH 7 by addition of 3N NaOH. Samples of
 acetone dicarboxylic acid (51 g, 0.15 mol) and (3,4-methylenedioxy)
 phenethylamine (20 g, 0.12 mol) were added and the mixture stirred at 25°C
 for two days. The mixture was made basic by addition of 100 mL of 3N NaOH,
 10 was extracted with EtOAc, washed with brine, dried (K₂CO₃) and concentrated.
 The residue was flash chromatographed using 20% acetone in hexane. The
 product was a crystalline solid. MS *m/z* (MH⁺) 274. ¹H NMR 300 MHz (CDCl₃)
 δ 6.6 (m, 3H), 5.9 (s, 2H), 3.5 (br. m, 2H), 2.85 (s, 4H), 2.65 (dd, 2H), 2.2 (d,
 2H), 2.05 (m, 2H), 1.7 (q, 2H).

15

Procedure G

Ethyl [[8-(2-benzo[1,3]dioxol-5-ylethyl)-8-azabicyclo[3:2:1] oct-3-ylidene]phenylmethyl]benzoate

Following the protocol of Procedure C and substituting 8-(2-benzo[1,3]dioxol-5-
 20 ylethyl)-8-azabicyclo[3.2.1]octan-3-one for 8-phenethyl-8-
 azabicyclo[3.2.1]octan-3-one, the title compound was obtained. MS *m/z* (MH⁺)
 496.

Procedure H**[[8-(2-Benzo[1,3]dioxol-5-ylethyl)-8-azabicyclo[3:2:1]
oct-3-ylidene]phenylmethyl]benzoic Acid**

- 5 Following the protocol of Procedure D and substituting ethyl-[[8-(2-benzo[1,3]dioxol-5-ylethyl)-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzoate for ethyl-4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoate, the title compound was obtained. MS *m/z* (MH⁺) 468.

10

Procedure J**[[8-(2-Benzo[1,3]dioxol-5-ylethyl)-8-azabicyclo[3:2:1]
oct-3-ylidene]phenylmethyl]benzoyl Chloride**

- Following the protocol of Procedure E and substituting [[8-(2-benzo[1,3]dioxol-5-ylethyl)-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzoic acid for 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoic acid, the title compound was obtained.

15

Example 48

20 **N-Ethyl-[[8-(2-Benzo[1,3]dioxol-5-ylethyl)-8-azabicyclo[3:2:1]
oct-3-ylidene]phenylmethyl]benzamide**

- Following the procedure of Example 23 and substituting [[8-(2-benzo[1,3]dioxol-5-ylethyl)-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzoyl chloride for 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoyl chloride, the title compound was obtained. MS *m/z* (MH⁺) 495.

25

Example 49

30 **N,N-Diethyl-[[8-(2-Benzo[1,3]dioxol-5-ylethyl)-8-azabicyclo[3:2:1]
oct-3-ylidene]phenylmethyl]benzamide**

- Following the procedure of Example 23 and substituting [[8-(2-benzo[1,3]dioxol-5-ylethyl)-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzoyl chloride for 4-[(8-phenethyl-8-

azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoyl chloride and diethyl amine for ethylamine hydrochloride, the title compound was obtained. MS m/z (MH^+) 523.

5

Procedure K

**Ethyl 4-[(8-methyl-8-azabicyclo[3.2.1]
oct-3-ylidene)phenylmethyl]benzoate**

Following the protocol of Procedure C and substituting tropinone for 8-phenethyl-8-azabicyclo[3.2.1]octan-3-one, the title compound was obtained.

10 MS m/z (MH^+) 362.Procedure L

**4-[(8-Methyl-8-azabicyclo[3.2.1]
oct-3-ylidene)phenylmethyl]benzoic Acid**

15 Following the protocol of Procedure D and substituting ethyl 4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoate for ethyl 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoate, the title compound was obtained. MS m/z (MH^+) 334

20

Procedure M

**4-[(8-Methyl-8-azabicyclo[3.2.1]
oct-3-ylidene)phenylmethyl]benzoyl Chloride**

Following the protocol of Procedure E and substituting 4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoic acid for 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoic acid, the title compound

25

was obtained.

Example 50

**N-Ethyl-4-[(8-Methyl-8-azabicyclo[3.2.1]
oct-3-ylidene)phenylmethyl]benzamide**

30

Following the protocol of Example 26 and substituting 4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoyl chloride for 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoyl chloride, the

title compound was obtained. MS m/z (MH^+) 361.

Example 51

N-Ethyl-4-[(8-azabicyclo[3.2.1]

oct-3-ylidene)phenylmethyl]benzamide

Following the protocol of Example 2 and substituting N-ethyl-4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide for N,N-diethyl-4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide, the title compound was obtained. MS m/z (MH^+) 347.

Example 52

N-Ethyl-4-[(8-allyl-8-azabicyclo[3.2.1]

oct-3-ylidene)phenylmethyl]benzamide

Following the protocol of Example 6 and substituting N-ethyl-4-[(8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide for N,N-diethyl-4-[(8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide, the title compound was obtained. MS m/z (MH^+) 387.

Procedure N

8-[2-(4-Methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]octanone

Following the protocol of Procedure F and substituting (4-methoxy)phenethylamine for (3,4-methylenedioxy)phenethylamine, the title compound was obtained. MS m/z (MH^+) 260.

Procedure O

Ethyl 4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]

oct-3-ylidene]phenylmethyl]benzoate

Following the protocol of Procedure C and substituting 8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]octanone for 8-phenethyl-8-azabicyclo[3.2.1]octan-3-one, the title compound was obtained. MS m/z (MH^+) 482.

Procedure P

**4-[[8-[2-(4-Methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]
oct-3-ylidene]phenylmethyl]benzoic Acid**

Following the protocol of Procedure D and substituting ethyl 4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzoate
5 for ethyl 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoate, the title compound was obtained.

Procedure Q

10 **4-[[8-[2-(4-Methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]
oct-3-ylidene]phenylmethyl]benzoyl Chloride**

Following the protocol of Procedure E and substituting 4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzoic acid for 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoic acid, the title compound was obtained.

15

Example 53

**N,N-Diethyl-4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]
oct-3-ylidene]phenylmethyl]benzamide**

Following the protocol of Procedure F and substituting 4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzoyl
20 chloride for 4-[(8-phenethyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzoyl chloride, the title compound was obtained. MS m/z (MH^+) 509.

25

Examples 54-63

**N,N-Di- R^2 , R^3 -4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]
oct-3-ylidene]phenylmethyl]benzamides**

Using the method of Example 26 and substituting the material from Procedure Q for the material from Procedure E, the following compounds were prepared:

30

Ex #	Amine	CIMS (MH^+)
54	morpholine	523
55	ethylamine	481

56	bis(methoxyethyl)amine	569
57	pyrrolidine	507
58	<i>cis</i> -2,6-dimethylpiperidine	549
59	N-ethyl-(N-methylallyl)amine	535
60	di- <i>n</i> -propylamine	537
61	2,2,6,6-tetramethylpiperidine	577
62	di-2-propylamine	537

Procedure R

N-Ethyl-4-(4-methoxybenzoyl)benzamide

Following the protocol of Procedure A and substituting 4-(4-methoxybenzoyl)benzoic acid for 4-benzoylbenzoic acid and ethylamine hydrochloride for diethylamine, the title compound was obtained. MS *m/z* (MH⁺) 284.

Example 63

10 N-Ethyl-4-[(4-methoxyphenyl)-(8-methyl-8-azabicyclo[3:2:1]oct-3-ylidene)methyl]benzamide

Following the protocol of Example 1 and substituting N-ethyl-4-(4-methoxybenzoyl)benzamide for N,N-diethyl-4-benzoylbenzamide, the title compound was obtained. MS *m/z* (MH⁺) 391.

15

Procedure S

2,2,2-Trichloroethyl 3-[(ethylcarbamoylphenyl)-

(4-methoxyphenyl)methylene]-8-azabicyclo[3:2:1]octanecarboxylate

A solution of 1.95 g (5.0 mmol) of N-ethyl-4-[(4-methoxyphenyl)-(8-methyl-8-azabicyclo[3:2:1]oct-3-ylidene)methyl]benzamide, 1.03 mL (7.5 mmol) of 2,2,2-trichloroethyl chloroformate and 0.43 mL (2.5 mmol) of diisopropylethylamine was stirred in 50 mL of benzene and 1.38 g (10 mmol) of K₂CO₃ added. The mixture was heated at under reflux for 18 h. Another 0.51 mL of (3.75 mmol) of 2,2,2-trichloroethyl chloroformate and 0.21 mL (1.25 mmol) of diisopropylethylamine was added. The mixture was heated under reflux for 3h. The reaction was cooled and poured into H₂O. The organic layer was washed

with dilute HCl and brine, dried (MgSO₄) and concentrated to give 2.09 g of a yellow gum. MS *m/z* (MH⁺) 553. ¹H NMR 300 MHz (CDCl₃) δ 7.7 (d, 2H), 7.2 (d, 2H), 7.0 (d, 2H), 6.8 (d, 2H), 6.2 br. s, 1H), 4.9 (d, 1H), 4.7 (d, 1H), 4.3 (br. m, 2H), 3.8 (s, 3H), 3.4 (q, 2H), 2.4 (br. m, 4H), 1.9 (m, 2H), 1.7 (m, 2H), 1.2 (t, 3H).

Procedure T

2,2,2-Trichloroethyl 3-[(ethylcarbamoylphenyl)-(4-hydroxyphenyl)methylene]-8-azabicyclo[3:2:1]octanecarboxylate

10 A solution of 1.03 g (1.82 mmol) of 2,2,2-trichloroethyl 3-[(ethylcarbamoylphenyl)-(4-methoxyphenyl)methylene]-8-azabicyclo[3:2:1]octanecarboxylate in 10 mL of CHCl₃ was cooled to -60°C under N₂ and 9.1 mL of 1M BBr₃ in CH₂Cl₂ was added dropwise. The cooling bath was removed and the mixture stirred at 25°C for 18 h. Saturated aqueous
15 NaHCO₃ was added and the CH₂Cl₂ was evaporated. The solid (1 g) was collected. ¹H NMR 300 MHz (CDCl₃) δ 7.8 (d, 2H), 7.2 (d, 2H), 6.9 (d, 2H), 6.7 (d, 2H), 6.2 (br. s, 1H), 4.9 (d, 1H), 4.7 (d, 1H), 4.4 (br. m, 2H), 3.4 (q, 2H), 2.4 (br. m, 4H), 1.9 (m, 2H), 1.7 (m, 2H), 1.2 (t, 3H).

20

Example 64

4-[(8-Azabicyclo[3:2:1]oct-3-ylidene)-(4-hydroxyphenyl)methyl]-N-ethylbenzamide

A 0.73 g sample (11 mmol) of zinc dust was added to a solution of 0.89 g (1.61 mmol) of 2,2,2-trichloroethyl 3-[(ethylcarbamoylphenyl)-(4-
25 hydroxyphenyl)methylene]-8-azabicyclo[3:2:1]octanecarboxylate in 9 mL of glacial HOAc. The mixture was heated under reflux for 5 h then cooled and the solid removed by filtration and washed with HOAc. The solvent was evaporated and K₂CO₃ was added. The mixture was extracted six times with 20% EtOH in CHCl₃. The solution was dried (Na₂SO₄) and concentrated. The
30 residue was crystallized from EtOH/2-PrOH to give 0.24 g of a white solid. MS *m/z* (MH⁺) 363. ¹H NMR (DMSO-d₆) δ 8.5 (t, 1H), 7.8 (d, 2H), 7.2 (d, 2H), 6.9 (d, 2H), 6.7 (d, 2H), 3.3 (br. m, 4H), 2.2 (br. m, 4H), 1.5 (m, 4H), 1.1 (t, 3H).

Procedure U**N-Diethyl-4-(4-methoxybenzoyl)benzamide**

A mixture of 0.75 g (5.5 mmol) of 4-methoxybenzeneboronic acid, 1.5 g (5 mmol) N,N-diethyl-4-iodobenzamide, 0.1 g (0.15 mmol) bistrisphenylphosphine
5 palladium(II)dichloride and 2.07 g (15 mmol) of K₂CO₃ in 30 mL of anisole was
flushed with carbon monoxide then heated at 80°C under a CO atmosphere for
5 h. The mixture was filtered and the solvent evaporated. The residue was
flash chromatographed 20% acetone in hexane to give the title compound. MS
m/z (MH⁺) 312.

10

Example 65**N,N-Diethyl-4-[(4-methoxyphenyl)-(8-methyl-8-azabicyclo[3:2:1]
oct-3-ylidene)methyl]benzamide**

Following the protocol of Example 1 and substituting N,N-diethyl-4-(4-
15 methoxybenzoyl)benzamide for N,N-diethyl-4-benzoylbenzamide, the title
compound was obtained. MS *m/z* (MH⁺) 419.

Procedure V

**2,2,2-Trichloroethyl 3-[(diethylcarbamoylphenyl)-
20 (4-methoxyphenyl)methylene]-8-azabicyclo[3:2:1]octanecarboxylate**
Following the protocol of Procedure S and substituting N,N-diethyl-4-[(4-
methoxyphenyl)-(8-methyl-8-azabicyclo[3:2:1]oct-3-ylidene)methyl]benzamide
for N-ethyl-4-[(4-methoxyphenyl)-(8-methyl-8-azabicyclo[3:2:1]oct-3-
ylidene)methyl]benzamide, the title compound was obtained.

25

Procedure W

**2,2,2-Trichloroethyl 3-[(diethylcarbamoylphenyl)-
(4-hydroxyphenyl)methylene]-8-azabicyclo[3:2:1]octanecarboxylate**
Following the protocol of Procedure T and substituting 2,2,2-trichloroethyl 3-
30 [(diethylcarbamoylphenyl)-(4-methoxyphenyl)methylene]-8-
azabicyclo[3:2:1]octanecarboxylate for 2,2,2-trichloroethyl 3-
[(ethylcarbamoylphenyl)-(4-methoxyphenyl)methylene]-8-
azabicyclo[3:2:1]octanecarboxylate, the title compound was obtained.

Example 66**4-[(8-Azabicyclo[3:2:1]oct-3-ylidene)-
(4-hydroxyphenyl)methyl]-N-diethylbenzamide**

- 5 Following the protocol for Example 64 and substituting 2,2,2-trichloroethyl 3-
[(diethylcarbamoylphenyl)-(4-hydroxyphenyl)methylene]-8-
azabicyclo[3:2:1]octanecarboxylate for 2,2,2-trichloroethyl 3-
[(ethylcarbamoylphenyl)-(4-hydroxyphenyl)methylene]-8-
azabicyclo[3:2:1]octanecarboxylate, the title compound was obtained. MS *m/z*
10 (MH⁺) 391.

Example 67**N,N-Diethyl-4-[(4-methoxyphenyl)-[8-[2-(4-methoxyphenyl)ethyl]-
8-azabicyclo[3:2:1]oct-3-ylidene)methyl]benzamide**

- 15 Following the protocol of Example 1 and substituting 8-[2-(4-
methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]octanone for tropinone, the title
compound was obtained. MS *m/z* (MH⁺) 539.

Example 68

20 **N,N-Diethyl-4-[(4-hydroxyphenyl)-[8-[2-(4-hydroxyphenyl)ethyl]-
8-azabicyclo[3:2:1]oct-3-ylidene)methyl]benzamide**

- Following the protocol of Example 64 and substituting N,N-diethyl-4-[(4-
methoxyphenyl)-[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]oct-3-
ylidene)methyl]benzamide for 2,2,2-trichloroethyl 3-[(ethylcarbamoylphenyl)-(4-
25 hydroxyphenyl)methylene]-8-azabicyclo[3:2:1]octanecarboxylate, the title
compound was obtained. MS *m/z* (MH⁺) 511.

Example 69

30 **N-Ethyl-4-[[8-[2-(4-hydroxyphenyl)ethyl]-8-azabicyclo[3:2:1]
oct-3-ylidene]phenylmethyl]benzamide**

- Following the protocol of Procedure T and substituting N-ethyl-4-[[8-[2-(4-
methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]
benzamide for 2,2,2-trichloroethyl 3-[(ethylcarbamoylphenyl)-(4-methoxy

phenyl)methylene]-8-azabicyclo[3:2:1]octanecarboxylate, the title compound was obtained. MS m/z (MH^+) 467.

Example 70

5 **N,N-Diethyl-4-[[8-[2-(4-hydroxyphenyl)ethyl]-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzamide**

Following the protocol of Procedure T and substituting N,N-diethyl-4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3:2:1]oct-3-ylidene]phenylmethyl]benzamide for 2,2,2-trichloroethyl 3-

10 [(ethylcarbamoylphenyl)-(4-methoxyphenyl)methylene]-8-azabicyclo[3:2:1]octanecarboxylate, the title compound was obtained. MS m/z (MH^+) 495.

Biological Examples

15 *Screening Assay for δ -Opioid and μ -Opioid Receptor Binding* *Rat Brain δ -Opioid Receptor Binding Assay*

The activity of the compounds of the invention as analgesics was demonstrated by the rat brain δ -opioid receptor binding assay as described below.

20

Procedure

Male, Wistar rats (150-250 g, VAF, Charles River, Kingston, NY) are killed by cervical dislocation, and their brains removed and placed immediately in ice cold Tris HCl buffer (50 mM, pH 7.4). The forebrains are separated from the

25 remainder of the brain by a coronal transection, beginning dorsally at the colliculi and passing ventrally through the midbrain-pontine junction. After dissection, the forebrains are homogenized in Tris buffer in a Teflon[®]-glass homogenizer. The homogenate is diluted to a concentration of 1 g of forebrain tissue per 100 mL Tris buffer and centrifuged at 39,000 X G for 10 min. The
30 pellet is resuspended in the same volume of Tris buffer with several brief pulses from a Polytron homogenizer. This particulate preparation is used for the δ -opioid binding assays. Following incubation with the δ -selective peptide ligand [³H]DPDPE at 25°C, the tube contents are filtered through Whatman

GF/B filter sheets on a Brandel cell harvester. The tubes and filters are rinsed three times with 4 mL of 10 mM HEPES (pH 7.4), and the radioactivity associated with the filter circles determined using Formula 989 scintillation fluid (New England Nuclear, Boston, MA) in a scintillation counter.

5

Analysis

The data are used to calculate either the % inhibition compared to control binding (when only a single concentration of test compound is evaluated) or a K_i value (when a range of concentrations is tested).

10

% Inhibition was calculated as follows:

$$1 - \left[\frac{(\text{test compound dpm} - \text{nonspecific dpm})}{(\text{total dpm} - \text{nonspecific dpm})} \right] \times 100\%$$

15

K_i value is calculated using the LIGAND (Munson, P.J. and Rodbard, D., Anal. Biochem. 107: 220-239, 1980) data analysis program.

20

Table 3 shows the biological activity (in K_i value) for 10nM solutions of the present compounds as measured in the rat brain δ -opioid receptor binding assay.

Table 3

Example #	δK_i (nM)	Example #	δK_i (nM)	Example #	δK_i (nM)
1	1.2	25	9.9	48	48.2
2	0.1	26	7.5	49	4.96
3	0.023	27	46.7	50	8.5
4	0.36	28	4.7	51	5.7
5	0.06	29	35.9	52	0.75
6	0.025	30	35.2	53	2.9
7	2.6	31	49	54	57
8	13	32	16.6	55	225
9	3.5	33	24	56	24
10	1.4	34	11	57	15
11	0.38	35	2.9	58	18
12	18.5	36	7.4	59	3.9
13	6.3	37	352	60	12
14	1.1	38	32	61	15.5
15	6.8	39	49	62	30.7
17	0.23	40	102	64	4.5
18	0.39	41	331	66	0.58
19	0.7	42	924	67	24.7
20	0.01	43	1520	68	0.41
21	0.56	44	178	69	1.08
22	92	45	19.8	70	0.7
23	0.23	46	404		
24	42.1	47	3.2		

Rat Brain μ -Opioid Receptor Binding Assay

- 5 The activity of compounds of the invention as analgesics is demonstrated by the rat brain μ -opioid receptor binding assay as described below.

Procedure

Male, Wistar rats (150-250 g, VAF, Charles River, Kingston, NY) are killed by cervical dislocation and their brains removed and placed immediately in ice cold Tris HCl buffer (50 mM, pH 7.4). The forebrains are separated from the remainder of the brain by a coronal transection, beginning dorsally at the colliculi and passing ventrally through the midbrain-pontine junction. After dissection, the forebrains are homogenized in Tris buffer in a Teflon®-glass homogenizer. The homogenate is diluted to a concentration of 1 g of forebrain tissue per 100 mL Tris buffer and centrifuged at 39,000 X G for 10 min. The pellet is resuspended in the same volume of Tris buffer with several brief pulses from a Polytron homogenizer. This particulate preparation is used for the μ -opioid binding assays. Following incubation with the m-selective peptide ligand [3 H]DAMGO at 25 °C, the tube contents are filtered through Whatman GF/B filter sheets on a Brandel cell harvester. The tubes and filters are rinsed three times with 4 mL of 10 mM HEPES (pH 7.4) and the radioactivity associated with the filter circles determined using Formula 989 scintillation fluid (New England Nuclear, Boston, MA) in a scintillation counter.

Analysis

The data are used to calculate either the % inhibition compared to control binding (when only a single concentration of test compound is evaluated) or a K_i value (when a range of concentrations is tested).

% Inhibition is calculated as follows:

$$1 - \left[\frac{(\text{test compound dpm} - \text{nonspecific dpm})}{(\text{total dpm} - \text{nonspecific dpm})} \right] \times 100\%$$

K_i value is calculated using the LIGAND (Munson, P.J. and Rodbard, D., Anal. Biochem. 107: 220-239, 1980) data analysis program.

Mouse Acetylcholine Bromide-Induced Abdominal Constriction Assay

The activity of compounds of the invention as analgesics was further demonstrated by the mouse acetylcholine bromide-induced abdominal

constriction assay as described below.

Procedure

The mouse acetylcholine-induced abdominal constriction assay (as described
5 by Collier et al. in *Brit. J. Pharmacol. Chem. Ther.*, **1968**, 32: 295-310 with
minor modifications) was used to assess analgesic potency of the compounds
of formula (I). The test drugs or appropriate vehicles were administered orally
(p.o.) and 30 min later the animal received an intraperitoneal (i.p.) injection of
5.5 mg/kg acetylcholine bromide (Matheson, Coleman and Bell, East
10 Rutherford, NJ). The mice were then placed in groups of three into glass bell
jars and observed for a ten min observation period for the occurrence of an
abdominal constriction response (defined as a wave of constriction and
elongation passing caudally along the abdominal wall, accompanied by a
twisting of the trunk and followed by extension of the hind limbs). For
15 compounds of the present invention, the percent inhibition of this response to a
nociceptive stimulus (equated to % analgesia) was calculated as follows:


% Inhibition of response (i.e., % analgesia) =

20
$$\frac{(\text{No. of control animal responses} - \text{No. of drug-treated animal responses})}{\text{No. of control animals responding}} \times 100$$

As a result of the mouse acetylcholine bromide-induced abdominal constriction
assay, the compound of Example 1 measured an 87% inhibition response at a
25 dose of 150 $\mu\text{mole/Kg}$ p.o.

WHAT IS CLAIMED IS:

1. An opioid receptor modulator compound selected from the group consisting of a δ -opioid and a μ -opioid receptor modulator compound of Formula (I):



(I)

5 wherein:

- R^1 is selected from the group consisting of hydrogen, C_{1-8} alkyl, halo $_{1-3}(C_{1-8})$ alkyl, C_{2-8} alkenyl, C_{1-8} alkoxy(C_{2-8})alkenyl, C_{2-8} alkynyl, C_{1-8} alkoxy(C_{2-8})alkynyl, cycloalkyl, cycloalkyl(C_{1-8})alkyl, cycloalkylcarbonyl(C_{1-8})alkyl, cycloalkyl(C_{2-8})alkenyl, cycloalkyl(C_{2-8})alkynyl, heterocyclyl, heterocyclyl(C_{1-8})alkyl, heterocyclylcarbonyl(C_{1-8})alkyl, heterocyclyl(C_{2-8})alkenyl, heterocyclyl(C_{2-8})alkynyl, aryl, aryl(C_{1-8})alkyl, arylcarbonyl(C_{1-8})alkyl, aryl(C_{2-8})alkenyl, aryl(C_{2-8})alkynyl, arylaminocarbonyl(C_{1-8})alkyl, heteroaryl(C_{1-8})alkyl, heteroarylcarbonyl(C_{1-8})alkyl, heteroaryl(C_{2-8})alkenyl, heteroaryl(C_{2-8})alkynyl, heteroarylaminocarbonyl(C_{1-8})alkyl, $(R^{1a})_2-N-(C_{1-8})$ alkyl, $R^{1a}-O-(C_{1-8})$ alkyl, $R^{1a}-S-(C_{1-8})$ alkyl, $R^{1a}-SO-(C_{1-8})$ alkyl and $R^{1a}-SO_2-(C_{1-8})$ alkyl; wherein heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} alkoxy, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkylcarbonyl, C_{1-6} alkylcarbonyloxy, C_{1-6} alkylcarbonylamino, C_{1-6} alkylthio, C_{1-6} alkylsulfonyl, halogen, hydroxy, oxo, cyano, trifluoromethyl and trifluoromethoxy; and, wherein aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} alkoxy, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino,

C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy;

- 5 R^{1a} is independently selected from the group consisting of hydrogen, C₁₋₈alkyl, C₁₋₈alkoxy(C₁₋₈)alkyl, hydroxy(C₁₋₈)alkyl, halo₁₋₃(C₁₋₈)alkyl, halo₁₋₃(C₁₋₈)alkoxy(C₁₋₈)alkyl, C₂₋₈alkenyl, C₂₋₈alkynyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl, heterocyclyl(C₁₋₈)alkenyl, heterocyclyl(C₁₋₈)alkynyl, aryl, aryl(C₁₋₈)alkyl, aryl(C₁₋₈)alkenyl, aryl(C₁₋₈)alkynyl, arylcarbonyl(C₁₋₈)alkyl, heteroaryl, heteroaryl(C₁₋₈)alkyl, heteroaryl(C₁₋₈)alkenyl, heteroaryl(C₁₋₈)alkynyl and heteroarylcarbonyl(C₁₋₈)alkyl; wherein heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, oxo, cyano, trifluoromethyl and trifluoromethoxy; and, wherein aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy;
- 25 R² is selected from the group consisting of aryl and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminocarbonyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy; alternatively, when aryl and heteroaryl are substituted with two substituents attached to adjacent carbon atoms, the two substituents can together form a single fused moiety; wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

R³ is selected from the group consisting of aryl and heteroaryl optionally substituted with one or two substituents in addition to the -A-Z moiety independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminocarbonyl, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy; alternatively, when aryl and heteroaryl are substituted with two optional substituents attached to adjacent carbon atoms, the two substituents can together form a single fused moiety; wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

A is selected from the group consisting of -C(=X)- and -SO₂-;

15

X is selected from the group consisting of O and S;

Z is selected from the group consisting of -O(R⁴) and -N(R⁵)(R⁶);

R⁴ is selected from the group consisting of hydrogen, C₁₋₈alkyl (optionally substituted with one to three halogen substituents), C₁₋₈alkoxy(C₁₋₈)alkyl, C₂₋₈alkenyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl, aryl, aryl(C₁₋₈)alkyl, heteroaryl, heteroaryl(C₁₋₈)alkyl, amino(C₁₋₈)alkyl, C₁₋₈alkylamino(C₁₋₈)alkyl, di(C₁₋₈)alkylamino(C₁₋₈)alkyl and hydroxy(C₁₋₈)alkyl; wherein heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen, hydroxy, oxo and cyano; and, wherein aryl is optionally substituted with one to four substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, -OCH₂O-, -O(CH₂)₂O-, trifluoromethyl, halogen, hydroxy and cyano; and,

R⁵ and R⁶ are independently selected from the group consisting of hydrogen,

C₁₋₈alkyl (optionally substituted with one to three halogen substituents),
 C₁₋₈alkoxy(C₁₋₈)alkyl, C₂₋₈alkenyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl,
 heterocyclyl, heterocyclyl(C₁₋₈)alkyl, aryl, aryl(C₁₋₈)alkyl, heteroaryl,
 heteroaryl(C₁₋₈)alkyl, amino(C₁₋₈)alkyl, C₁₋₈alkylamino(C₁₋₈)alkyl,
 5 di(C₁₋₈)alkylamino(C₁₋₈)alkyl, aminoimino, aminocarbonyl,
 aminocarbonyl(C₁₋₈)alkyl, aryloxy carbonylamino(C₁₋₈)alkyl,
 heteroaryloxy carbonylamino(C₁₋₈)alkyl, hydroxy(C₁₋₈)alkyl and
 trifluoro(C₁₋₄)alkoxy; wherein heterocyclyl is optionally substituted with one
 to three substituents independently selected from the group consisting of
 10 C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen,
 hydroxy, oxo and cyano; and, wherein aryl is optionally substituted with one
 to four substituents independently selected from the group consisting of
 C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, -OCH₂O-, -O(CH₂)₂O-,
 trifluoromethyl, halogen, hydroxy and cyano; alternatively, R⁵ and R⁶ may,
 15 together with the nitrogen to which they are attached, form a fused
 heterocyclyl moiety optionally substituted with one to four substituents
 independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy,
 C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen, hydroxy and cyano;

20 and pharmaceutically acceptable enantiomers, diastereomers and salts
 thereof.

2. The compound of claim 1 wherein R¹ is selected from the group
 consisting of hydrogen, C₁₋₈alkyl, C₂₋₈alkenyl, C₂₋₈alkynyl, cycloalkyl,
 25 cycloalkyl(C₁₋₈)alkyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl,
 heterocyclylcarbonyl(C₁₋₈)alkyl, aryl(C₁₋₈)alkyl, arylcarbonyl(C₁₋₈)alkyl,
 aryl(C₂₋₈)alkynyl, arylaminocarbonyl(C₁₋₈)alkyl, heteroaryl(C₁₋₈)alkyl,
 (R^{1a})₂-N-(C₁₋₈)alkyl and R^{1a}-O-(C₁₋₈)alkyl; wherein heterocyclyl is
 optionally substituted with one to three substituents independently
 30 selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, halogen,
 hydroxy, oxo and cyano; and, wherein aryl is optionally substituted with
 one to three substituents independently selected from the group
 consisting of C₁₋₆alkyl, C₁₋₆alkoxy, halogen, hydroxy and cyano.

3. The compound of claim 1 wherein R¹ is selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *t*-butyl, *n*-hexyl, butenyl, allyl, 3,3-dimethylallyl, cyclopropyl, cyclopropyl(C₁₋₃)alkyl, cyclohexyl, cyclohexyl(C₁₋₃)alkyl, pyrrolidinyl, pyrrolidinyl(C₁₋₃)alkyl, 5 1,3-dioxolanyl(C₁₋₃)alkyl, 2-imidazoliny, 2-imidazoliny(C₁₋₃)alkyl, imidazolidinyl, imidazolidinyl(C₁₋₃)alkyl, 2-pyrazolinyl, 2-pyrazolinyl(C₁₋₃)alkyl, pyrazolidinyl, pyrazolidinyl(C₁₋₃)alkyl, piperidinyl, piperidinyl(C₁₋₃)alkyl, morpholinyl, morpholinyl(C₁₋₃)alkyl, thiomorpholinyl, thiomorpholinyl(C₁₋₃)alkyl, piperazinyl, piperazinyl(C₁₋₃)alkyl, [4-(C₁₋₃)alkyl- 10 5-oxo-1,4-dihydrotetrazol-1-yl](C₁₋₃)alkyl, piperonyl, (1,3-benzodioxol-5-yl)(C₂₋₃)alkyl, (2,3-dihydro-1,4-benzodioxin-6-yl)carbonyl(C₁₋₃)alkyl, (3,4-dihydro-2*H*-1,5-benzodioxepin-7-yl)carbonyl(C₁₋₃)alkyl, benzyl, phenyl(C₂₋₃)alkyl, phenyl(C₂₋₃)alkynyl, diphenyl(C₁₋₃)alkyl, phenylcarbonyl(C₁₋₃)alkyl, phenylaminocarbonyl(C₁₋₃)alkyl, furyl(C₁₋₃)alkyl, 15 thienyl(C₁₋₃)alkyl, pyrrolyl(C₁₋₃)alkyl, oxazolyl(C₁₋₃)alkyl, thiazolyl(C₁₋₃)alkyl, imidazolyl(C₁₋₃)alkyl, pyrazolyl(C₁₋₃)alkyl, isoxazolyl(C₁₋₃)alkyl, isothiazolyl(C₁₋₃)alkyl, 1,2,3-oxadiazolyl(C₁₋₃)alkyl, 1,2,3-triazolyl(C₁₋₃)alkyl, 1,3,4-thiadiazolyl(C₁₋₃)alkyl, pyridinyl(C₁₋₃)alkyl, pyridazinyl(C₁₋₃)alkyl, pyrimidinyl(C₁₋₃)alkyl, pyrazinyl(C₁₋₃)alkyl, 20 1,3,5-triazinyl(C₁₋₃)alkyl, indolyl(C₁₋₃)alkyl, benzo[b]furyl(C₁₋₃)alkyl, benzo[b]thienyl(C₁₋₃)alkyl, (R^{1a})₂-N-(C₁₋₃)alkyl and R^{1a}-O-(C₁₋₃)alkyl; wherein pyrrolidinyl, 2-imidazoliny, imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and piperazinyl are optionally substituted with one to three substituents selected from 25 oxo; and, wherein phenyl is optionally substituted with one to three substituents independently selected from the group consisting of methyl, ethyl, *n*-propyl, *n*-butyl, methoxy, ethoxy, propoxy, butoxy, chlorine, fluorine, hydroxy and cyano.
- 30 4. The compound of claim 1 wherein R¹ is selected from the group consisting of hydrogen, methyl, *n*-propyl, *n*-butyl, allyl, 3,3-dimethylallyl, cyclopropylmethyl, cyclohexylethyl, 2-(4-ethyl-5-oxo-1,4-dihydrotetrazol-1-yl)ethyl, piperonyl, 2-(1,3-benzodioxol-5-yl)ethyl, 2-(2,3-dihydro-1,4-

- benzodioxin-6-yl)-2-oxoethyl, 2-(3,4-dihydro-2*H*-1,5-benzodioxepin-7-yl)-2-oxoethyl, benzyl, phenethyl, phenylpropyl, phenoxyethyl, phenylcarbonylmethyl, phenylcarbonylethyl, phenylaminocarbonylmethyl, thienylmethyl, thienylethyl, imidazolymethyl, pyridinymethyl and indolylethyl; wherein phenyl is optionally substituted with one to three substituents independently selected from the group consisting of methoxy, fluorine, hydroxy and cyano.
- 5
- 10 5. The compound of claim 1 wherein R^{1a} is independently selected from the group consisting of hydrogen, C₁₋₆alkyl and aryl; wherein aryl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy.
- 15
- 20 6. The compound of claim 1 wherein R^{1a} is independently selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *t*-butyl and phenyl; wherein phenyl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, di(C₁₋₆alkyl)amino, halogen, trifluoromethyl and trifluoromethoxy.
- 25
7. The compound of claim 1 wherein R^{1a} is independently selected from the group consisting of methyl, ethyl and phenyl.
- 30 8. The compound of claim 1 wherein R² is selected from the group consisting of phenyl, naphthalenyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, indolyl, benzo[b]furyl and benzo[b]thienyl

- optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₃alkyl, C₂₋₃alkenyl, C₁₋₃alkoxy, amino, C₁₋₃alkylamino, di(C₁₋₃alkyl)amino, C₁₋₃alkylcarbonyl, C₁₋₃alkylcarbonyloxy, C₁₋₃alkylcarbonylamino, chlorine, fluorine, hydroxy, trifluoromethyl and trifluoromethoxy.
- 5
9. The compound of claim 1 wherein R² is selected from the group consisting of phenyl, furyl, thienyl, pyridinyl and benzo[b]furyl optionally substituted with one substituent selected from the group consisting of methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino, methylcarbonyl, methylcarbonyloxy, methylcarbonylamino, fluorine, hydroxy, trifluoromethyl and trifluoromethoxy.
- 10
10. The compound of claim 1 wherein R² is selected from phenyl optionally substituted with one substituent selected from the group consisting of methoxy and hydroxy.
- 15
11. The compound of claim 1 wherein R³ is selected from the group consisting of phenyl, naphthalenyl, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, indolyl, benzo[b]furyl and benzo[b]thienyl optionally substituted with one or two substituents in addition to the -A-Z moiety independently selected from the group consisting of methyl, ethyl, *n*-propyl, *i*-propyl, allyl, methoxy, ethoxy, amino, C₁₋₃alkylamino, di(C₁₋₃)alkylamino, C₁₋₃alkylcarbonyl, C₁₋₃alkylcarbonyloxy, C₁₋₃alkylcarbonyl, C₁₋₃alkylaminocarbonyl, C₁₋₃alkylcarbonylamino, C₁₋₃alkylthio, C₁₋₃alkylsulfonyl, chloro, fluoro, hydroxy, cyano, trifluoromethyl and trifluoromethoxy; alternatively, when phenyl is substituted with two optional substituents attached to adjacent carbon atoms, the two substituents can together form a single fused moiety; wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅-
- 20
- 25
- 30

and $-O(CH_2)_{1-3}O-$.

12. The compound of claim 1 wherein R^3 is phenyl substituted with the moiety -A-Z at the 3 or 4 position.
13. The compound of claim 1 wherein A is $-C(=X)-$.
14. The compound of claim 1 wherein Z is $-N(R^5)(R^6)$.
15. The compound of claim 1 wherein R^4 is selected from the group consisting of C_{1-8} alkyl (optionally substituted with one to three halogen substituents), C_{2-8} alkenyl, aryl and aryl(C_{1-8})alkyl; wherein aryl is optionally substituted with one to two substituents independently selected from the group consisting of C_{1-8} alkyl, $-OCH_2O-$, $-O(CH_2)_2O-$ and halogen.
16. The compound of claim 1 wherein R^4 is selected from the group consisting of C_{1-3} alkyl (optionally substituted with one or three fluorine substituents), C_{2-4} alkenyl, phenyl and benzyl; wherein phenyl is optionally substituted with one to two substituents independently selected from the group consisting of C_{1-3} alkyl, $-OCH_2O-$, $-O(CH_2)_2O-$ and fluorine.
17. The compound of claim 1 wherein R^4 is selected from the group consisting of methyl, ethyl, 3-methyl, phenyl and benzyl; wherein phenyl is optionally substituted with one substituent selected from the group consisting of methyl and fluorine.
18. The compound of claim 1 wherein R^5 and R^6 are independently selected from the group consisting of hydrogen, C_{1-4} alkyl, fluoro(C_{1-3})alkyl, trifluoro(C_{1-3})alkyl, C_{1-3} alkoxy(C_{1-3})alkyl, C_{2-5} alkenyl, cyclopropyl, cyclopropyl(C_{1-3})alkyl, cyclopentyl, cyclopentyl(C_{1-3})alkyl, cyclohexyl, cyclohexyl(C_{1-3})alkyl, pyrrolidinyl, pyrrolidinyl(C_{1-3})alkyl, 1,3-dioxolanyl,


1,3-dioxolanyl(C₁₋₃)alkyl, 2-imidazoliny, 2-imidazoliny(C₁₋₃)alkyl,
 imidazolidiny, imidazolidiny(C₁₋₃)alkyl, 2-pyrazoliny,
 2-pyrazoliny(C₁₋₃)alkyl, pyrazolidiny(C₁₋₃)alkyl, piperidiny,
 piperidiny(C₁₋₃)alkyl, morpholiny, morpholiny(C₁₋₃)alkyl, thiomorpholiny,
 5 thiomorpholiny(C₁₋₃)alkyl, piperaziny, piperaziny(C₁₋₃)alkyl, piperonyl,
 phenyl, benzyl, phenyl(C₂₋₃)alkyl, furyl, furyl(C₁₋₃)alkyl, thienyl,
 thienyl(C₁₋₃)alkyl, pyrrolyl(C₁₋₃)alkyl, oxazolyl, oxazolyl(C₁₋₃)alkyl, thiazolyl,
 thiazolyl(C₁₋₃)alkyl, imidazolyl, imidazolyl(C₁₋₃)alkyl, pyrazolyl,
 pyrazolyl(C₁₋₃)alkyl, isoxazolyl, isoxazolyl(C₁₋₃)alkyl, isothiazolyl,
 10 isothiazolyl(C₁₋₃)alkyl, 1,2,3-oxadiazolyl, 1,2,3-oxadiazolyl(C₁₋₃)alkyl,
 1,2,3-triazolyl, 1,2,3-triazolyl(C₁₋₃)alkyl, 1,3,4-thiadiazolyl,
 1,3,4-thiadiazolyl(C₁₋₃)alkyl, pyridiny, pyridiny(C₁₋₃)alkyl, pyridaziny,
 pyridaziny(C₁₋₃)alkyl, pyrimidiny, pyrimidiny(C₁₋₃)alkyl, pyraziny,
 pyraziny(C₁₋₃)alkyl, 1,3,5-triaziny, 1,3,5-triaziny(C₁₋₃)alkyl,
 15 indolyl(C₁₋₃)alkyl, benzo[b]furyl, benzo[b]furyl(C₁₋₃)alkyl, benzo[b]thienyl,
 benzo[b]thienyl(C₁₋₃)alkyl, benzimidazolyl, benzimidazolyl(C₁₋₃)alkyl,
 amino(C₁₋₃)alkyl, C₁₋₃alkylamino(C₁₋₃)alkyl, di(C₁₋₃)alkylamino(C₁₋₃)alkyl,
 aminoimino, hydroxy(C₁₋₃)alkyl and trifluoro(C₁₋₄)alkoxy; wherein
 pyrrolidiny, 1,3-dioxolanyl, 2-imidazoliny, imidazolidiny, 2-pyrazoliny,
 20 pyrazolidiny, piperidiny, morpholiny, thiomorpholiny, piperaziny are
 optionally substituted with one to three substituents independently
 selected from the group consisting of C₁₋₄alkyl and oxo; and, wherein
 phenyl is optionally substituted with one to four substituents
 independently selected from the group consisting of C₁₋₄alkyl, C₁₋₄alkoxy,
 25 -OCH₂O-, -O(CH₂)₂O-, halogen, hydroxy and cyano; alternatively, R⁵ and
 R⁶ may, together with the nitrogen to which they are attached, form a
 fused heterocyclyl moiety selected from the group consisting of
 pyrrolidiny, imidazolidiny, pyrazolidiny, piperidiny, morpholiny,
 thiomorpholiny and piperaziny optionally substituted with one to four
 30 substituents independently selected from C₁₋₄alkyl.

19. The compound of claim 1 wherein R⁵ and R⁶ are independently selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl, *i*-propyl,

t -butyl, fluoro(C₁₋₃)alkyl, methoxy(C₁₋₃)alkyl, methallyl, cyclopropyl,
 cyclohexyl, phenyl, thiazolyl, imidazolyl(C₁₋₃)alkyl,
 benzimidazolyl(C₁₋₃)alkyl, dimethylamino(C₁₋₃)alkyl and
 hydroxy(C₁₋₃)alkyl; wherein phenyl is optionally substituted with one to
 5 three substituents selected from fluorine; alternatively, R⁵ and R⁶ may,
 together with the nitrogen to which they are attached, form a fused
 heterocyclyl moiety selected from the group consisting of pyrrolidinyl,
 piperidinyl and morpholinyl optionally substituted with one to four
 substituents independently selected from the group consisting of methyl,
 10 ethyl, n -propyl and n -butyl.

20. The compound of claim 1 wherein R⁵ and R⁶ are independently selected
 from the group consisting of hydrogen, methyl, ethyl, n -propyl, i -propyl,
 t -butyl, 2-fluoroethyl, methoxyethyl, methallyl, cyclopropyl, cyclohexyl,
 phenyl, thiazolyl, 2-(2-imidazolyl)ethyl, benzimidazolylmethyl,
 15 dimethylaminopropyl and hydroxyethyl; wherein phenyl is optionally
 substituted with fluorine; alternatively, R⁵ and R⁶ may, together with the
 nitrogen to which they are attached, form a fused heterocyclyl moiety
 selected from the group consisting of pyrrolidinyl, piperidinyl and
 morpholinyl; wherein piperidinyl is substituted with two or four
 20 substituents selected from methyl.

21. The compound of claim 1 of the formula:



wherein the moiety $-C(=X)-$ is substituted on phenyl at the 3 or 4 position and

R¹, -C(=X)- and Z are dependently selected from the group consisting of:


R ¹	-C(=X)-	Z
methyl	-4-C(=O)-	N,N-diethylamino;
H	-4-C(=O)-	N,N-diethylamino;
allyl	-4-C(=O)-	N,N-diethylamino;
2-(4-fluorophenyl)ethyl	-4-C(=O)-	N,N-diethylamino;
2-(2-thienyl)ethyl	-4-C(=O)-	N,N-diethylamino;
2-(3-indolyl)ethyl	-4-C(=O)-	N,N-diethylamino;
2-cyclohexylethyl	-4-C(=O)-	N,N-diethylamino;
2-phenoxyethyl	-4-C(=O)-	N,N-diethylamino;
2-(4-ethyl-5-oxo-1,4-dihydropyridazin-1-yl)ethyl	-4-C(=O)-	N,N-diethylamino;
2-phenyl-2-oxoethyl	-4-C(=O)-	N,N-diethylamino;
2-(4-methoxyphenyl)-2-oxoethyl	-4-C(=O)-	N,N-diethylamino;
2-(3-cyanophenyl)-2-oxoethyl	-4-C(=O)-	N,N-diethylamino;
2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl	-4-C(=O)-	N,N-diethylamino;
2-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-2-oxoethyl	-4-C(=O)-	N,N-diethylamino;
propyl	-4-C(=O)-	N,N-diethylamino;
2-phenylethyl	-4-C(=O)-	N,N-diethylamino;
piperonyl	-4-C(=O)-	N,N-diethylamino;
3-phenylpropyl	-4-C(=O)-	N,N-diethylamino;
methyl	-3-C(=O)-	N-methyl-N-(3-fluorophenyl)amino;
2-phenylethyl	-4-C(=S)-	N,N-diethylamino;
2-phenylethyl	-4-C(=O)-	N-ethylamino;
2-phenylethyl	-4-C(=O)-	amino;
2-phenylethyl	-4-C(=O)-	4-morpholinyl;
2-phenylethyl	-4-C(=O)-	N,N-diisopropylamino;
2-phenylethyl	-4-C(=O)-	N,N-bis(methoxyethyl)amino;
2-phenylethyl	-4-C(=O)-	1-pyrrolidinyl;
2-phenylethyl	-4-C(=O)-	2,6-dimethyl-1-piperidinyl;

2-phenylethyl	-4-C(=O)-	N-ethyl-N-(methylallyl)amino;
2-phenylethyl	-4-C(=O)-	N,N-dipropylamino;
2-phenylethyl	-4-C(=O)-	N- <i>t</i> -butylamino;
2-phenylethyl	-4-C(=O)-	N-(2-fluoroethyl)amino;
2-phenylethyl	-4-C(=O)-	N-(2-thiazolyl)amino;
2-phenylethyl	-4-C(=O)-	N-(2-methoxyethyl)amino;
2-phenylethyl	-4-C(=O)-	N-(1 <i>H</i> -benzimidazol-2-ylmethyl)amino;
2-phenylethyl	-4-C(=O)-	N-cyclohexylamino;
2-phenylethyl	-4-C(=O)-	N-phenylamino;
2-phenylethyl	-4-C(=O)-	N-[2-(2-imidazolyl)ethyl]amino;
2-phenylethyl	-4-C(=O)-	N-cyclopropylamino;
2-phenylethyl	-4-C(=O)-	N,N-(dimethylaminopropyl)amino;
2-phenylethyl	-4-C(=O)-	N-ethyl-N-(hydroxyethyl)amino;
2-(1,3-benzodioxol-5-yl)ethyl	-4-C(=O)-	N-ethylamino;
2-(1,3-benzodioxol-5-yl)ethyl	-4-C(=O)-	N,N-diethylamino;
methyl	-4-C(=O)-	N-ethylamino;
H	-4-C(=O)-	N-ethylamino;
allyl	-4-C(=O)-	N-ethylamino;
2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N,N-diethylamino;
2-(4-methoxyphenyl)ethyl	-4-C(=O)-	4-morpholinyl;
2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N-ethylamino;
2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N,N-bis(2-methoxyethyl)amino;
2-(4-methoxyphenyl)ethyl	-4-C(=O)-	1-pyrrolidinyl;
2-(4-methoxyphenyl)ethyl	-4-C(=O)-	2,6-dimethyl-1-piperidinyl;
2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N-ethyl-N-(methylallyl)amino;
2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N,N-(di- <i>n</i> -propyl)amino;
2-(4-methoxyphenyl)ethyl	-4-C(=O)-	2,2,6,6-tetramethyl-1-piperidinyl;
2-(4-methoxyphenyl)ethyl	-4-C(=O)-	N,N-(di-2-propyl)amino;
2-(4-hydroxyphenyl)ethyl	-4-C(=O)-	N-ethylamino; and,

2-(4-hydroxyphenyl)ethyl -4-C(=O)- N,N-diethylamino;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

5 22. The compound of claim 1 of the formula:



wherein R¹, R², R⁵ and R⁶ are dependently selected from the group consisting of:

R¹	R²	(R⁵)(R⁶)
methyl	4-MeOPh	(H)(Et);
H	4-HOPh	(H)(Et) ;
methyl	4-MeOPh	Et₂;
H	4-HOPh	Et₂;
2-(4-MeOPh)ethyl	4-MeOPh	Et₂; and,
2-(4-HOPh)ethyl	4-HOPh	Et₂;


10 and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

23. The compound of claim 1 which is an effective analgesic.

15 24. The compound of claim 1 which is an effective immunosuppressant, antiinflammatory agent, agent for the treatment of neurological and psychiatric conditions, medicament for drug and alcohol abuse, agent

for treating gastritis and diarrhea, cardiovascular agent or agent for the treatment of respiratory diseases.

25. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
26. A method for the treatment of a pharmacological condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an opioid receptor modulator compound selected from the group consisting of a δ -opioid and a μ -opioid receptor modulator compound of Formula (I):



(I)

wherein:

- R¹ is selected from the group consisting of hydrogen, C₁₋₈alkyl, halo₁₋₃(C₁₋₈)alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy(C₂₋₈)alkenyl, C₂₋₈alkynyl, C₁₋₈alkoxy(C₂₋₈)alkynyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, cycloalkylcarbonyl(C₁₋₈)alkyl, cycloalkyl(C₂₋₈)alkenyl, cycloalkyl(C₂₋₈)alkynyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl, heterocyclylcarbonyl(C₁₋₈)alkyl, heterocyclyl(C₂₋₈)alkenyl, heterocyclyl(C₂₋₈)alkynyl, aryl, aryl(C₁₋₈)alkyl, arylcarbonyl(C₁₋₈)alkyl, aryl(C₂₋₈)alkenyl, aryl(C₂₋₈)alkynyl, arylaminocarbonyl(C₁₋₈)alkyl, heteroaryl(C₁₋₈)alkyl, heteroarylcarbonyl(C₁₋₈)alkyl, heteroaryl(C₂₋₈)alkenyl, heteroaryl(C₂₋₈)alkynyl, heteroarylaminocarbonyl(C₁₋₈)alkyl, (R^{1a})₂-N-(C₁₋₈)alkyl, R^{1a}-O-(C₁₋₈)alkyl, R^{1a}-S-(C₁₋₈)alkyl, R^{1a}-SO-(C₁₋₈)alkyl and R^{1a}-SO₂-(C₁₋₈)alkyl; wherein heterocyclyl is optionally substituted with one to three substituents

independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, oxo, cyano, trifluoromethyl and trifluoromethoxy; and, wherein aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy;

R^{1a} is independently selected from the group consisting of hydrogen, C₁₋₈alkyl, C₁₋₈alkoxy(C₁₋₈)alkyl, hydroxy(C₁₋₈)alkyl, halo₁₋₃(C₁₋₈)alkyl, halo₁₋₃(C₁₋₈)alkoxy(C₁₋₈)alkyl, C₂₋₈alkenyl, C₂₋₈alkynyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl, heterocyclyl(C₁₋₈)alkenyl, heterocyclyl(C₁₋₈)alkynyl, aryl, aryl(C₁₋₈)alkyl, aryl(C₁₋₈)alkenyl, aryl(C₁₋₈)alkynyl, arylcarbonyl(C₁₋₈)alkyl, heteroaryl, heteroaryl(C₁₋₈)alkyl, heteroaryl(C₁₋₈)alkenyl, heteroaryl(C₁₋₈)alkynyl and heteroarylcarbonyl(C₁₋₈)alkyl; wherein heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, oxo, cyano, trifluoromethyl and trifluoromethoxy; and, wherein aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy;

R² is selected from the group consisting of aryl and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino,

di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy,
 C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminocarbonyl, C₁₋₆alkylcarbonylamino,
 C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and
 trifluoromethoxy; alternatively, when aryl and heteroaryl are substituted with
 5 two substituents attached to adjacent carbon atoms, the two substituents
 can together form a single fused moiety; wherein the moiety is selected
 from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

R³ is selected from the group consisting of aryl and heteroaryl optionally
 10 substituted with one or two substituents in addition to the -A-Z moiety
 independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl,
 C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl,
 C₁₋₆alkylcarbonyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminocarbonyl,
 C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy,
 15 cyano, trifluoromethyl and trifluoromethoxy; alternatively, when aryl and
 heteroaryl are substituted with two optional substituents attached to
 adjacent carbon atoms, the two substituents can together form a single
 fused moiety; wherein the moiety is selected from the group consisting of
 -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

20

A is selected from the group consisting of -C(=X)- and -SO₂-;

X is selected from the group consisting of O and S;

25 Z is selected from the group consisting of -O(R⁴) and -N(R⁵)(R⁶);

R⁴ is selected from the group consisting of hydrogen, C₁₋₈alkyl (optionally
 substituted with one to three halogen substituents), C₁₋₈alkoxy(C₁₋₈)alkyl,
 C₂₋₈alkenyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, heterocyclyl,
 30 heterocyclyl(C₁₋₈)alkyl, aryl, aryl(C₁₋₈)alkyl, heteroaryl, heteroaryl(C₁₋₈)alkyl,
 amino(C₁₋₈)alkyl, C₁₋₈alkylamino(C₁₋₈)alkyl, di(C₁₋₈)alkylamino(C₁₋₈)alkyl and
 hydroxy(C₁₋₈)alkyl; wherein heterocyclyl is optionally substituted with one to
 three substituents independently selected from the group consisting of

C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen, hydroxy, oxo and cyano; and, wherein aryl is optionally substituted with one to four substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, -OCH₂O-, -O(CH₂)₂O-,
 5 trifluoromethyl, halogen, hydroxy and cyano; and,

R⁵ and R⁶ are independently selected from the group consisting of hydrogen, C₁₋₈alkyl (optionally substituted with one to three halogen substituents), C₁₋₈alkoxy(C₁₋₈)alkyl, C₂₋₈alkenyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl,
 10 heterocyclyl, heterocyclyl(C₁₋₈)alkyl, aryl, aryl(C₁₋₈)alkyl, heteroaryl, heteroaryl(C₁₋₈)alkyl, amino(C₁₋₈)alkyl, C₁₋₈alkylamino(C₁₋₈)alkyl, di(C₁₋₈)alkylamino(C₁₋₈)alkyl, aminoimino, aminocarbonyl, aminocarbonyl(C₁₋₈)alkyl, aryloxy carbonylamino(C₁₋₈)alkyl, heteroaryloxy carbonylamino(C₁₋₈)alkyl, hydroxy(C₁₋₈)alkyl and
 15 trifluoro(C₁₋₄)alkoxy; wherein heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen, hydroxy, oxo and cyano; and, wherein aryl is optionally substituted with one to four substituents independently selected from the group consisting of
 20 C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, -OCH₂O-, -O(CH₂)₂O-, trifluoromethyl, halogen, hydroxy and cyano; alternatively, R⁵ and R⁶ may, together with the nitrogen to which they are attached, form a fused heterocyclyl moiety optionally substituted with one to four substituents independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy,
 25 C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen, hydroxy and cyano;


and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

30 27. The method of claim 26 wherein the therapeutically effective amount is from about 0.01 mg/day to about 15,000 mg/day.

28. The method of claim 26 wherein the δ -opioid or μ -opioid receptor

modulator compound is an effective analgesic.

29. The method of claim 26 wherein the δ -opioid or μ -opioid receptor modulator compound is an effective immunosuppressant, antiinflammatory agent, agent for the treatment of neurological and psychiatric conditions, medicament for drug and alcohol abuse, agent for treating gastritis and diarrhea, cardiovascular agent or agent for the treatment of respiratory diseases.
30. The method of claim 26 wherein the pharmacological condition is pain.
31. A pharmaceutical composition comprising a combination of a μ -opioid receptor modulator compound and an opioid receptor modulator compound selected from the group consisting of a δ -opioid and a μ -opioid receptor modulator compound of Formula (I):



(I)

wherein:

- R¹ is selected from the group consisting of hydrogen, C₁₋₈alkyl, halo₁₋₃(C₁₋₈)alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy(C₂₋₈)alkenyl, C₂₋₈alkynyl, C₁₋₈alkoxy(C₂₋₈)alkynyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, cycloalkylcarbonyl(C₁₋₈)alkyl, cycloalkyl(C₂₋₈)alkenyl, cycloalkyl(C₂₋₈)alkynyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl, heterocyclylcarbonyl(C₁₋₈)alkyl, heterocyclyl(C₂₋₈)alkenyl, heterocyclyl(C₂₋₈)alkynyl, aryl, aryl(C₁₋₈)alkyl, arylcarbonyl(C₁₋₈)alkyl, aryl(C₂₋₈)alkenyl, aryl(C₂₋₈)alkynyl,

arylaminocarbonyl(C₁₋₈)alkyl, heteroaryl(C₁₋₈)alkyl,
 heteroarylcarbonyl(C₁₋₈)alkyl, heteroaryl(C₂₋₈)alkenyl, heteroaryl(C₂₋₈)alkynyl,
 heteroarylaminocarbonyl(C₁₋₈)alkyl, (R^{1a})₂-N-(C₁₋₈)alkyl, R^{1a}-O-(C₁₋₈)alkyl,
 R^{1a}-S-(C₁₋₈)alkyl, R^{1a}-SO-(C₁₋₈)alkyl and R^{1a}-SO₂-(C₁₋₈)alkyl; wherein
 5 heterocyclyl is optionally substituted with one to three substituents
 independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl,
 C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl,
 C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl,
 halogen, hydroxy, oxo, cyano, trifluoromethyl and trifluoromethoxy; and,
 10 wherein aryl and heteroaryl are optionally substituted with one to three
 substituents independently selected from the group consisting of C₁₋₆alkyl,
 C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino,
 C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio,
 C₁₋₆alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and
 15 trifluoromethoxy;

R^{1a} is independently selected from the group consisting of hydrogen, C₁₋₈alkyl,
 C₁₋₈alkoxy(C₁₋₈)alkyl, hydroxy(C₁₋₈)alkyl, halo₁₋₃(C₁₋₈)alkyl,
 halo₁₋₃(C₁₋₈)alkoxy(C₁₋₈)alkyl, C₂₋₈alkenyl, C₂₋₈alkynyl, cycloalkyl,
 20 cycloalkyl(C₁₋₈)alkyl, heterocyclyl, heterocyclyl(C₁₋₈)alkyl,
 heterocyclyl(C₁₋₈)alkenyl, heterocyclyl(C₁₋₈)alkynyl, aryl, aryl(C₁₋₈)alkyl,
 aryl(C₁₋₈)alkenyl, aryl(C₁₋₈)alkynyl, arylcarbonyl(C₁₋₈)alkyl, heteroaryl,
 heteroaryl(C₁₋₈)alkyl, heteroaryl(C₁₋₈)alkenyl, heteroaryl(C₁₋₈)alkynyl and
 heteroarylcarbonyl(C₁₋₈)alkyl; wherein heterocyclyl is optionally substituted
 25 with one to three substituents independently selected from the group
 consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino,
 di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy,
 C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, halogen, hydroxy,
 oxo, cyano, trifluoromethyl and trifluoromethoxy; and, wherein aryl and
 30 heteroaryl are optionally substituted with one to three substituents
 independently selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl,
 C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonyl,
 C₁₋₆alkylcarbonyloxy, C₁₋₆alkylcarbonylamino, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl,

halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy;

5 R^2 is selected from the group consisting of aryl and heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} alkoxy, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkylcarbonyl, C_{1-6} alkylcarbonyloxy, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylaminocarbonyl, C_{1-6} alkylcarbonylamino, C_{1-6} alkylthio, C_{1-6} alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy; alternatively, when aryl and heteroaryl are substituted with
10 two substituents attached to adjacent carbon atoms, the two substituents can together form a single fused moiety; wherein the moiety is selected from the group consisting of $-(CH_2)_{3-5}-$ and $-O(CH_2)_{1-3}O-$;

15 R^3 is selected from the group consisting of aryl and heteroaryl optionally substituted with one or two substituents in addition to the -A-Z moiety independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} alkoxy, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkylcarbonyl, C_{1-6} alkylcarbonyloxy, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylaminocarbonyl, C_{1-6} alkylcarbonylamino, C_{1-6} alkylthio, C_{1-6} alkylsulfonyl, halogen, hydroxy, cyano, trifluoromethyl and trifluoromethoxy; alternatively, when aryl and
20 heteroaryl are substituted with two optional substituents attached to adjacent carbon atoms, the two substituents can together form a single fused moiety; wherein the moiety is selected from the group consisting of $-(CH_2)_{3-5}-$ and $-O(CH_2)_{1-3}O-$;

25

A is selected from the group consisting of $-C(=X)-$ and $-SO_2-$;

X is selected from the group consisting of O and S;

30 Z is selected from the group consisting of $-O(R^4)$ and $-N(R^5)(R^6)$;

R^4 is selected from the group consisting of hydrogen, C_{1-8} alkyl (optionally substituted with one to three halogen substituents), C_{1-8} alkoxy(C_{1-8})alkyl,

C₂₋₈alkenyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl, heterocyclyl,
 heterocyclyl(C₁₋₈)alkyl, aryl, aryl(C₁₋₈)alkyl, heteroaryl, heteroaryl(C₁₋₈)alkyl,
 amino(C₁₋₈)alkyl, C₁₋₈alkylamino(C₁₋₈)alkyl, di(C₁₋₈)alkylamino(C₁₋₈)alkyl and
 hydroxy(C₁₋₈)alkyl; wherein heterocyclyl is optionally substituted with one to
 5 three substituents independently selected from the group consisting of
 C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen,
 hydroxy, oxo and cyano; and, wherein aryl is optionally substituted with one
 to four substituents independently selected from the group consisting of
 C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, -OCH₂O-, -O(CH₂)₂O-,
 10 trifluoromethyl, halogen, hydroxy and cyano; and,

R⁵ and R⁶ are independently selected from the group consisting of hydrogen,
 C₁₋₈alkyl (optionally substituted with one to three halogen substituents),
 C₁₋₈alkoxy(C₁₋₈)alkyl, C₂₋₈alkenyl, cycloalkyl, cycloalkyl(C₁₋₈)alkyl,
 15 heterocyclyl, heterocyclyl(C₁₋₈)alkyl, aryl, aryl(C₁₋₈)alkyl, heteroaryl,
 heteroaryl(C₁₋₈)alkyl, amino(C₁₋₈)alkyl, C₁₋₈alkylamino(C₁₋₈)alkyl,
 di(C₁₋₈)alkylamino(C₁₋₈)alkyl, aminoimino, aminocarbonyl,
 aminocarbonyl(C₁₋₈)alkyl, aryloxycarbonylamino(C₁₋₈)alkyl,
 heteroaryloxycarbonylamino(C₁₋₈)alkyl, hydroxy(C₁₋₈)alkyl and
 20 trifluoro(C₁₋₄)alkoxy; wherein heterocyclyl is optionally substituted with one
 to three substituents independently selected from the group consisting of
 C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen,
 hydroxy, oxo and cyano; and, wherein aryl is optionally substituted with one
 to four substituents independently selected from the group consisting of
 25 C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl, cycloalkyl, -OCH₂O-, -O(CH₂)₂O-,
 trifluoromethyl, halogen, hydroxy and cyano; alternatively, R⁵ and R⁶ may,
 together with the nitrogen to which they are attached, form a fused
 heterocyclyl moiety optionally substituted with one to four substituents
 independently selected from the group consisting of C₁₋₆alkyl, C₁₋₆alkoxy,
 30 C₂₋₆alkenyl, cycloalkyl, trifluoromethyl, halogen, hydroxy and cyano;

and pharmaceutically acceptable enantiomers, diastereomers and salts
 thereof.

32. The pharmaceutical composition of claim 31 wherein the μ -opioid receptor modulator compound is selected from alfentanil, allylprodine, alphaprodine, anileridine, bezitramide, buprenorphine, clonitazene, cyclazocine, dextromoramide, dihydrocodeine, dihydromorphine, ethoheptazine, ethylmorphine, etonitazene, fentanyl, heroin, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, lofentanil, meperidine, meptazinol, metazocine, methadone, morphine, nalbuphine, norlevorphanol, normethadone, nalorphine, normorphine, opium, oxycodone, oxymorphone, phenazocine, piritramide, propiram, propoxyphene, sufentanil, tramadol or diastereomers, salts, complexes and mixtures thereof of any of the foregoing.
33. A method for the treatment of a pharmacological condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 31.
34. The method of claim 33 wherein the therapeutically effective amount is from about 0.01 mg/day to about 15,000 mg/day.
35. The method of claim 33 wherein the pharmaceutical composition is an effective analgesic.
36. The method of claim 33 wherein the pharmaceutical composition is an effective immunosuppressant, antiinflammatory agent, agent for the treatment of neurological and psychiatric conditions, medicament for drug and alcohol abuse, agent for treating gastritis and diarrhea, cardiovascular agent or agent for the treatment of respiratory diseases.
37. The method of claim 33 wherein the pharmacological condition is pain.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 September 2001 (13.09.2001)

PCT

(10) International Publication Number
WO 01/66543 A3

- (51) International Patent Classification?: C07D 451/02, A61K 31/46, A61P 37/06
- (21) International Application Number: PCT/US01/05735
- (22) International Filing Date: 22 February 2001 (22.02.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/186,778 3 March 2000 (03.03.2000) US
- (71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ 08869-0602 (US).
- (72) Inventors: CARSON, John, R.: 551 Rittenhouse Boulevard, Norristown, PA 19403 (US). COATS, Steven, J.: 1029 Brayton Court, Quakertown, PA 18951 (US). NEILSON, Lou, Anne: 1210 Diamond Street, Sellersville, PA 18960 (US). WU, Wu-Nan: 2043 Spring Valley Road, Lansdale, PA 19446 (US). BOYD, Robert, E.: 84 Wynmere Drive, Horsham, PA 19044 (US). PITIS, Philip, M.: 108 Sunrise Drive, North Wales, PA 19454 (US).
- (74) Agents: JOHNSON, Philip, S. et al.: Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
--- with international search report
- (88) Date of publication of the international search report:
14 March 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 3-(DIARYLMETHYLENE)-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES

(57) Abstract: This invention is directed to 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives useful as δ -opioid or μ -opioid receptor modulators. Depending on their agonist or antagonist effect, the compounds are useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.

WO 01/66543 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/05735

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D451/02 A61K31/46 A61P37/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PATENT ABSTRACTS OF JAPAN vol. 018, no. 443 (C-1239), 18 August 1994 (1994-08-18) -& JP 06 135965 A (TORAY IND INC), 17 May 1994 (1994-05-17) abstract	1-37
Y	WO 98 28275 A (WEI ZHONGYONG ;DELORME DANIEL (CA); ROBERTS EDWARD (CA); ASTRA PHA) 2 July 1998 (1998-07-02) cited in the application page 1, line 11 - line 19 page 2, formula (I) page 9, line 20 -page 10, line 25 examples	1-37

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

24 October 2001

Date of mailing of the international search report

02/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hoepfner, W

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/05735

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 06135965	A	17-05-1994	NONE	
WO 9828275	A	02-07-1998	AU 737999 B2	06-09-2001
			AU 5351298 A	17-07-1998
			BR 9714055 A	09-05-2000
			CN 1246111 A	01-03-2000
			CZ 9902199 A3	17-11-1999
			EE 9900256 A	15-12-1999
			EP 0946511 A1	06-10-1999
			JP 2001507350 T	05-06-2001
			NO 993022 A	20-08-1999
			PL 334374 A1	28-02-2000
			WO 9828275 A1	02-07-1998
			SK 76299 A3	08-11-1999
			TR 9901417 T2	21-10-1999
			US 6187792 B1	13-02-2001
			US 2001021715 A1	13-09-2001
			HU 0000610 A2	28-09-2000